xx
x5JUMF".VMUJDFOUFS
3BOEPNJ[FE
%PVCMF#MJOE
1MBDFCP$POUSPM MFE4UVEZUP&WBMVBUFUIF
&GGJDBDZBOE4BGFUZPG"MPHMJQUJO$PNQBSFE8JUI1MBDFCPJO1FEJ BUSJD4VCKFDUT8JUI5ZQF
%JBCFUFT.FMMJUVT
/$5/VNCFS/$51SPUPDPM"QQSPWF%BUF"VHVTU
&HUWDLQLQIRUPDWLRQZLWKLQWKLVSURWRFROKDVEHHQUHGDFWHGLH VSHFLILFFRQWHQWLVPDVNHGLUUHYHUVLEO\IURP
YLHZZLWKDEODFNEOXH EDUWRSURWHFWHLWKHUSHUVRQDOO\LGHQWLILDEOHLQIRUPDWLRQ33' RUFRPSDQ\
FRQILGHQWLDOLQIRUPDWLRQ&&,
7KLVPD\LQFOXGHEXWLVQRWOLPLWHGWRUHGDFWLRQRIWKHIROOR ZLQJ
1DPHGSHUVRQVRURUJDQL]DWLRQVDVVRFLDWHGZLWKWKHVWXG\
3URSULHWDU\LQIRUPDWLRQVXFKDVVFDOHVRUFRGLQJV\VWHPVZKLF KDUHFRQVLGHUHGFRQILGHQWLDO
LQIRUPDWLRQXQGHUSULRUDJUHHPHQWVZLWKOLFHQVHKROGHU
2WKHULQIRUPDWLRQDVQHHGHGWRSURWHFWFRQILGHQWLDOLW\RI7DNHG DRUSDUWQHUVSHUVRQDOLQIRUPDWLRQRU
WRRWKHUZLVHSURWHFWWKHLQWHJULW\RIWKHFOLQLFDOVWXG\C
CI
1.0 TITLE PAGE
PROTOCOL
A Multicenter, Randomized, Double -Blind, Placebo -Controlled Study to Evaluate the 
Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 
Diabetes Mellitus
Phase 3 Aloglipti nPediatric Study
Sponsor: Takeda Development Center Americas, Inc 
95 Hay den Avenue, 
Lexington, MA 02421 USA
Takeda Development Centre Europe Ltd.
1 Kingdo m Street
London, W2 68D
UK
Takeda Development Center Asia Pte. L td.
2 Shenton Way, #15 -02 SGX Centre 1, 
Singapore 068804
Study Number: SYR -322_309
IND Number: 69,707 EudraCT Number: 2015-000208-25
Compound: aloglipt in
Date: 17August 2020 Amendment Number: 9IT v 1
Amendment History : 
Date Amendment Number Amendment Type Region
17August 2020 Amendment 9 IT v1 Substantial Italy
13November 2019 Amendment 8 Substantial Russia
28November 20 18 Amendment 7 Substantial Brazil
27June 2018 Amendment 6 Substantial Germany
09February  2018 Amendment 5 Substantial Germany
17January 2018 Amendment 4 Substantial Italy
10May 2017 Amendment 3 Nonsubstantial Global
09November 20 16 Amendment 2 Substantial Global
29April 2016 Amendment 1 Substantial Global
28July 2015 Initial Protocol Not applicable Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 2 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
1.0 ADMINISTRATIVE INFORMATION
1.1 Contacts 
A separate contact information list will be provided to each site.Takeda Development Center (TDC) sponsored investigators per individual country requirements 
will be provided with emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. 
Contact 
Type/Role North American Contact South American Contact European Contact
Serious adverse event and 
pregnancy 
reporting
Medical Monitor(medical advice on 
protocol and 
compound)
Responsible Medical Officer 
(carries 
overall responsibility for the conduct of the study)PPD
Property of Takeda: a:Applicable Terms of Usequiquiremremii
yy each seachyy
r assigneassign
EAp
o the A
: For Non-Commercial Use Only and Subject to t
Alogliptin
Study No. SYR-322_309 Page 3 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
1.2 Approval 
REPRESENTATIVES OF TAKEDA 
This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice (GCP): Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Userdance dance
wing:wing
P): ConsP): Con
ta privaa priva
other sither s
: For Non-Commercial Use Only and Su
Alogliptin
Study No. SYR -322_309 Page 4of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igatorâ€™s Brochure, and any 
other product information provided by the sponsor. I agree to conduct this study  in accordance 
with the requirements of this protocol and also to protect the rights, safet y, privacy, and well -being 
of study  subjects in accordance with the following:
ï‚·The ethical principles that have their origin in the Declaration of Helsinki.
ï‚·Internationa l Conference on Harmonisation, E6 GCP: Consolidated Guideline.
ï‚·All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
ï‚·Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
ï‚·Terms outlined in the Clinical Study  Site Agreement.
ï‚·Appendix B-Responsibilit ies of the Investigator.
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igatorâ€™s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 5of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
1.3 Protocol Amendment No. 9 IT v1 Summary of Changes 
This sect ion describes the changes in reference to the protocol incorporating Amendment 9 IT v1.
The primary  reasons for thi s amendment are to:
ï‚·Describe how to manage study  procedures, data collect ion, invest igational product, and 
statist ical analysis during unavo idable circumstance s such as the coronavirus disease 2019 
(COVID -19) pandemic. 
ï‚·Revise the sample size as per United States ( US) Food and Drug Administration ( FDA) 
recommendat ion and in accordance wit h the approved European Medicines Agency (EMA) 
modified Paediatri c Investi gational Plan (PIP), EMEA -
000496- PIP01 - 08- M08. 
ï‚·Remove the specific dropout/hy perglycemic rescue rate of 30%, as recommended by  the US 
FDA. 
ï‚·Update the text to include the recent availabilit y of liraglut ide for type 2 di abetes mellitus 
(T2DM) treatm ent in children and ado lescents. 
ï‚·Remove pharmacogenomic sampling.
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct of the study  are included for clarification and administrative purposes onl y.
Protocol Amendment 9 IT v1
Summary of Changes Since the Last Version of the Approved Protocol for Italy
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 2.0STUDY SUMMARY
Section 13.3 Determination of
Sample SizeReduced the sample size from 100 
subjects per arm to 75 subjects per arm.To revise the sample size as per US 
FDA recommendation and in 
accordance with the approved EMA 
modified PIP, 
EMEA -000496 -PIP01 -08-M08.
Section 2.0STUDY SUMMARY
Section 13.3 Determination of
Sample SizeRem oved the specific 
dropout/hyperglycemic rescue rate of 
30%.To remove the specific 
dropout/hyperglycemic rescue rate 
of 30% as recommended by US 
FDA.
Section 4.1Background Updated text to reflect availability of 
liraglutide for c hildren and adolescents 
aged 10 to 17 years.To update text to include current 
availability  of liraglutide for 
treatment of T2DM in children and 
adolescents aged 10 to 17 years.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 6of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Protocol Amendment 9 IT v1
Summary of Changes Since the Last Version of the Approved Protocol for Italy
Sections Affected by Change Description of Each Change and Rationale
Section 6.1Study Design
Section 7.6Criteria for 
Discontinuation or Withdrawal of a 
Study Drug
Section 8.2Investigational Drug 
Assignment and Dispensing 
Procedures
Section 9.1.1 Alternative 
Approaches to Study Procedures and 
Data Collection Due to Unavoidable 
Circumstances
Section 9.1.9 Procedures for Clinical 
Laborato ry Samples
Section 9.3Schedule of 
Observations and Procedures
Section 13.1 Statistical and 
Analy tical Plans
Section 14.2 Protocol Deviations
Appendix A Schedule of Study 
ProceduresAdded instructions for managing study 
procedures, dat a collection, and 
investigational product during 
unavoidable circumstances (eg, a 
widespread disease outbreak such as 
the COVID -19 pandemic or natural 
disaster).To provide instruction for 
managing study components 
impacted by unavoidable 
circumstances.
Section 9.1.2.1 Pharmacoge nomic 
Informed Consent Procedure
Section 9.1.12 Pharmacogenomi c 
Sample Collection
Section 9.4Biological Sample 
Retention and Destruction
Appendix A Schedule of Study 
ProceduresDiscontinued collection of 
pharmacogenomic sampleAs of the date of this amendment, a 
sufficient number of samples have 
been collected and no more are 
need ed.
Section 13.1.3 Efficacy Analysis Added sensitivity analysis for the 
primary  endpoint only  that excludes 
subjects affected by COVID -19.To add sensitivity analysis to the 
primary  endpoint.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 7 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
TABLE OF CONTENTS
1.0 ADMINISTRATIVE INFORMATION ...........................................................................2
1.1 Contacts .................................................................................................................... .2
1.2 Approval .................................................................................................................... 3
1.3 Protocol Amendment No. 9 IT v1 Summary of  Change s............................................5
2.0 STUDY SUMMARY ....................................................................................................13
3.0 STUDY REFERENCE INFORMATION ......................................................................17
3.1 Study-Related Responsibilities .................................................................................17
3.2 Coordinating Investigator .........................................................................................17
3.3 List of Abbreviations ...............................................................................................18
3.4 Corporate Identification ...........................................................................................19
4.0 INTRODUCTI ON.........................................................................................................20
4.1 Background .............................................................................................................20
4.2 Rationale for the P roposed St udy.............................................................................22
5.0 STUDY OBJECTIVES AND ENDPOINTS ..................................................................22
5.1 Objectives ................................................................................................................22
5.1.1 Prima ry Objective ............................................................................................22
5.1.2 Secondary Ob jectives ......................................................................................22
5.1.3 Exploratory Objectives ....................................................................................23
5.2 Endpoints .................................................................................................................23
5.2.1 Prima ry Endpoint .............................................................................................23
5.2.2 Secondary Endpoints .......................................................................................23
5.2.3 .....................................................................................24
6.0 STUDY DESIGN AND DE SCRIPTION .......................................................................25
6.1 Study Design ...........................................................................................................256.2 Pre-Randomization Stabilization Period (if needed) .................................................27
6.3 Justification for Study Design, Dose, and Endpoints ................................................28
6.4 Premature Termination or Suspension of Study or Investigational Site .....................29
6.4.1 Criteria for Pr emature Termination or Suspension of the Study ........................29
6.4.2 Criteria for Prematu re Termination or Suspension of Investigational Sites .......29
6.4.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s) .............................................................29
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS ..............29
7.1 Inclusion Criteria .....................................................................................................297.2 Exclusion Criteria ....................................................................................................30CCI
Property of Takeda: For NonSIGN ASIGN
yyDesigDesyy
reeCommercial Use Only and Subject to the Applicable Terms of Use2
......22
.............. 3
.........
.............
...............
..............
.............
..........
..........
..............
..............
.............
S............
..............
............
.............
veses.....
.............
poointint..
yyEndpoEndpyy
-RandRa
JustJustif
44 P
6.on-C
Alogliptin
Study No. SYR -322_309 Page 8of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
7.3 Addit ional Rando mizat ion Cri teria That Mus t Be Met Following Screening and/or 
Com pletion of the Pre -Rando mizat ion Stabilizat ion Peri od...................................... 31
7.4 Excluded Medicat ions.............................................................................................. 32
7.5 Diet, Fl uid, Act ivity Control .................................................................................... 33
7.6 Criteria for Di scontinuati on or Wi thdrawal  of a Study  Drug ..................................... 33
7.7 Criteria for Di scontinuati on or Withdrawal fro m Study  Parti cipat ion....................... 34
7.7.1 Voluntary  Withdrawal ..................................................................................... 34
7.7.2 Lost- to-Follow -up............................................................................................ 35
7.8 Liver Safety  Moni toring and Wit hdrawal Criteria .................................................... 36
7.8.1 Liver Funct ion Test Monitoring ....................................................................... 36
7.8.2 Considerations for Temporary  Discont inuat ion of Study  Drug ......................... 36
7.8.3 Perm anent Discont inuat ion of Study  Drug ....................................................... 37
7.8.4 Re-initiation of Study  Drug ................................
.............................................. 37
7.9 Renal Safet y Withdrawal Criteria ............................................................................. 38
7.10 Pancreat itis Monitoring and Wit hdrawal Criteria ..................................................... 38
7.11 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 39
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ...................................................... 39
8.1 Study  Medicat ion and Materials ............................................................................... 39
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling .................................. 39
8.1.1.1 Invest igational Drug ................................................................................ 39
8.1.1.2 Com panion Medicati on............................................................................ 39
8.1.1.3 Sponsor -Supplied Drug ............................................................................ 40
8.1.1.4 Rescue Medicat ions................................................................................. 40
8.1.2 Storage ............................................................................................................ 40
8.1.3 Dose and Regimen ........................................................................................... 40
8.1.4 Overdose ......................................................................................................... 40
8.2 Invest igational Drug Assignment and Dispensing Procedures .................................. 41
8.3 Randomization Code Creation and Storage .............................................................. 41
8.4 Invest igational Drug Blind Maintenance .................................................................. 41
8.5 Unblinding Procedure .............................................................................................. 41
8.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 42
9.0 STUDY PLAN .............................................................................................................. 43
9.1 Study  Procedures ..................................................................................................... 43
9.1.1 Alternat ive Approaches to Study Procedures and Data Collect ion Due to 
Unavo idable Circumstances ............................................................................. 43
9.1.2 Inform ed Consent Procedure ............................................................................ 45
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 9 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
9.1.2.1 Pharmacogenomic Informed Consent Procedure ......................................45
9.1.3 Demographics, Medical History, and Medication History  Proce dure................45
9.1.4 Physical Examinat ion Proce dure......................................................................45
9.1.5 Weight, Height and BMI ..................................................................................46
9.1.6 Vital Sign Procedure ........................................................................................46
9.1.7 Documentation of Concomitant Medi cations ...................................................46
9.1.8 Documentation of Conc urrent Medical Conditions ...........................................47
9.1.8.1 Annual Ophthalmologic Examination ......................................................47
9.1.9 Procedures for Clinical La boratory Sa mples ....................................................47
9.1.9.1 2-Hour Postprandial Glucose Test ............................................................49
9.1.10 Contraception a nd Pregnancy Avoidance Procedure ........................................50
9.1.11 Pregnanc y........................................................................................................50
9.1.12 Pharmac ogenomic Sample Co llection ..............................................................51
9.1.13 ECG Proce dure................................................................................................52
9.1.14 52
9.1.14.1 ..................................52
9.1.14.2 .............................................................................53
9.1.15 Documentation of Screen F ailure or Pre-Randomization Stabilization Failures
........................................................................................................................53
9.1.16 Documentation of Randomization ....................................................................53
9.1.17 Blood Glucose Edu cation and Management .....................................................54
9.1.17.1 Education on Hypoglycemia ....................................................................54
9.1.17.2 Definitions of Hypoglycemia ...................................................................54
9.1.17.3 Criteria for Hyperglycemia Rescue ..........................................................55
9.1.18 Biomarkers of Bone Turnover ..........................................................................56
9.2 Monitoring Subject Treatment Comp liance ..............................................................56
9.3 Schedule of Observation s and Proce dures ................................................................57
9.3.1 Screenin g.........................................................................................................57
9.3.2 Pre-Rando mization S tabilization Period ...........................................................58
9.3.3 Week -1 ...........................................................................................................58
9.3.4 Randomization .................................................................................................58
9.3.5 Double-Blind Treatm ent Period .......................................................................58
9.3.6 Unscheduled  Visit (As Applicable) ..................................................................59
9.3.7 End-of-Treatme nt Visi t....................................................................................59
9.3.8 Follow-up Vi sit................................................................................................59
9.3.9 Pro jected Week 52 Visit ..................................................................................59CCI
CCI
CCI
Property of Takeda: FniiFor Non-Commercial Use Only..............
Failure Failu
................
Randoando m
Educatiduca
on on Hon on
initnitioionsn
Cririteriateriiii
omomarkearkand Subject to the Applicable Terms of Use455
.......4646
..............
................
............
.............
...............
.............
ee..........
...........
...............
................
toringtoriniiii
SchedulSched
9.3.1.3.1
9.3.29.3
9and 
nly a
Alogliptin
Study No. SYR -322_309 Page 10of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
9.3.10 Post Study  Care ............................................................................................... 59
9.4 Biological Sample Retent ion and Destruction .......................................................... 60
10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................ 60
10.1 Definit ions............................................................................................................... 60
10.1.1 PTEs ................................................................................................................ 60
10.1.2 AEs ................................................................................................................. 60
10.1.3 Addit ional Po ints to Consi der for PTEs and AEs ............................................. 61
10.1.4 SAEs ............................................................................................................... 63
10.1.5 Special Interest AEs......................................................................................... 64
10.1.6 Severit y of PTEs and AEs ................................................................................ 64
10.1.7 Causalit y of AEs................................ .............................................................. 65
10.1.8 Relationship to Study  Procedures ..................................................................... 65
10.1.9 Start Date ......................................................................................................... 65
10.1.10 Stop Date ......................................................................................................... 65
10.1.11 Frequency ........................................................................................................ 65
10.1.12 Action Concerning Study  Medicat ion.............................................................. 65
10.1.13 Outcom e.......................................................................................................... 66
10.2 Procedures ............................................................................................................... 66
10.2.1 Collect ion and Reporti ng of AEs ..................................................................... 66
10.2.1.1 PTE and AE Collection Period .................................................................66
10.2.1.2 PTE and AE Reporting ............................................................................ 66
10.2.1.3 Speci al Interest AE Reporting .................................................................. 67
10.2.2 Collect ion and Reporti ng of SAEs ................................................................... 68
10.2.3 Reporting of Abnormal Liver Function Tests ................................................... 68
10.3 Follow-up of  SAEs .................................................................................................. 68
10.3.1 Safety Reporting to Invest igato rs, IRBs or IECs, and Regulatory  Authori ties...68
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 69
11.1 Independent Data Monitoring Co mmittee ................................................................ 69
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 69
12.1 CRFs (El ectronic) .................................................................................................... 69
12.2 Record Retention ..................................................................................................... 70
13.0 STATIST ICAL METHODS .......................................................................................... 70
13.1 Statistical and Analyt ical Plans ................................................................................ 70
13.1.1 Analysis Sets ................................................................................................... 70
13.1.2 Analysis of Demographics and Other Baseline Characterist ics......................... 71
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 11of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
13.1.3 Efficacy Analysis ............................................................................................. 71
13.1.4 Pharmacokinet ic Analysis ................................................................................ 72
13.1.5 Safety Analysis ................................................................................................ 72
13.2 Interim Analysis and Criteria for Early Terminat ion................................................ 72
13.3 Determinat ion of Sample Size .................................................................................. 72
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 72
14.1 Study -Site Moni toring Visit s................................................................................... 72
14.2 Protocol  Deviat ions.................................................................................................. 72
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 73
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 73
15.1 IRB and/or IEC Approval ........................................................................................ 73
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 74
15.3 Subject Confidentialit y............................................................................................ 75
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................76
15.4.1 Publicat ion and Disclosure ............................................................................... 76
15.4.2 Clinical Trial Registration ................................................................................ 76
15.4.3 Clinical Trial Result s Disclosure ...................................................................... 76
15.5 Insurance and Co mpensation for Injury .................................................................... 76
16.0 REFERENCES .............................................................................................................. 77
LIST OF IN -TEXT TABLES
Table 8.a Dose and Regimen ............................................................................................. 40
Table 9.a Clinical Laboratory  Tests ................................................................................... 48
Table 9.b Flowchart of PPG Test ....................................................................................... 50
Table10.a Takeda Medically Significant AE List ................................................................ 64
LIST OF IN -TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 26
LIST OF APPENDICES
Appendix ASchedule of Study  Procedures ............................................................................ 80
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 83
Appendix C Elements of the Subject Informed Consent ......................................................... 85
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 12of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix D Invest igator Consent to Use of Person al Information.......................................... 88
Appendix E Collect ion, Shipment, and Storage of Pharmacokinetic Samples ......................... 89
Appendix F Collect ion, Shipment, and Storage of Pharmacogeno mic Samples ...................... 92
Appendix G Determinat ion of Eligibilit y in Subjects Wit h Elevated ALT Levels ................... 93
Appendix H Reco mmendat ions for Home Gl ucose Moni toring .............................................. 94
Appendix I Protocol  History.................................................................................................95
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 13 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
2.0 STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc. 
Takeda Development Centre Europe Ltd.
Takeda Development Center Asia Pte. Ltd.Compound:
Alogliptin
Title of Protocol: A Multicenter, Randomized, 
Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus IND No.: 69,707 EudraCT No. : 
2015-000208-25
Study Number: SYR-322_309 Phase: 3
Study Design:
This will be a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of 
alogliptin 25 mg once daily (QD) compared to placebo, in children and adolescents 10 to 17 years, inclusive, at the 
time of randomization, with a confirmed diagnosis of type  2 diabetes mellitus (T2DM) and who are experiencing 
inadequate glycemic control. Subjects will enter into a Screening Period of up to 2 weeks. If certain entry criteria are not met, subjects will participate in a Pre-Randomization Stabilization Period. On Study Day 1, eligible subjects will be randomly assigned in a 1:1 ratio to 1 of 2 treatment  groups, alogliptin 25 mg QD or matching placebo. In addition to 
receiving double-blind study medication, subjects will be required to maintain their background antidiabetic therapy, 
at the same dose, throughout the first 26 weeks of the Double-Blind Treatment Period. Subjects who complete the 52-Week Double-Blind Treatment Period complete an End-of-Tr eatment Visit and Follow-Up Visit, 2 weeks after the 
End-of-Treatment Visit. Subjects who terminate doubl e-blind study drug prematurely will complete an 
End-of-Treatment Visit and Follow-Up Visit, 2 weeks after the End-of-Treatment Visit, and will continue to be 
followed for the 52-week duration of the st udy and complete a projected Week 52 Visit.
Primary Objective:
The primary objective of this study will be to evaluate the efficacy of alogliptin 25 mg QD compared to placebo when 
administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination 
of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in 
pediatric subjects with T2DM. 
Secondary Objectives:
To evaluate the HbA1c change from Baseline after treatment with alogliptin as compared with placebo at Weeks 12, 
18, 39, and 52.
To evaluate the safety of alogliptin compared to placebo by assessing: 
!The incidence of hypoglycemic events, treatment emergent adverse events (TEAEs), clinical laboratory 
parameters, electrocardiogram (ECG) readings, physical examinations, and vital signs at Weeks 26 and 52.
!The effects on biomarkers of bone turnover (bone-specific alkaline phosphatase and C-terminal telopeptide 
[CTX]) markers at Weeks 26 and 52.
!The effects on CD26 surface antigen levels at Weeks 26 and 52.
CCI
Property of Takeda: For Non-Cohange froange fr
ety of aloety of Fo nce of hyce of 
ers, elects, ele
effects offects
CTXCTX ])])Commercial Use On-Only and Subject to the valuatingvaluatin
cents 10 ents 1
tus (us (T2DT2D
of up to of up t
n Period.n Period
iptin 25 ptin 25
red to mad to m
-Blind TBlind 
d-ofof--ffffTreaTre Applicable Terms of Useofof
No.No.: :
002080208 -2eT
App
blind stblind 
ks after tafter
nd complnd compeA
e to evaluto eval
added onadded
ed by thed by thU
m
The efTheCo
pepeperty ofCCIC
Alogliptin
Study No. SYR-322_309 Page 14 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Subject Population: Pediatric subjects aged 10 to 17 years, inclusive, with T2DM.
Number of Subjects:
150 randomized subjectsNumber of Sites: 
Estimated total: 60 sites in 20 countries
Dose Level(s):
Alogliptin 25 mg QD
Placebo QDRoute of Administration:
Oral
Duration of Treatment:
52 weeksPeriod of Evaluation:
Approximately 56 weeks plus a variable 
Pre-Randomization Stabilization Period
Main Criteria for Inclusion:
A confirmed diagnosis of T2DM using American Diabetes Association (ADA) and World Health Organization 
(WHO) criteria (laboratory determinations of FPG â‰¥126 mg/dL, random glucose â‰¥200 mg/dL [ â‰¥11.10 mmol/L], 
HbA1c â‰¥6.5%, or 2-hour oral glucose tolerance test [OGTT] glucose â‰¥200 mg/dL), documented in the subjectsâ€™ 
medical record.
Main Criteria for Exclusion:
1. The subject has a confirmed diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young 
(MODY).
2. The subject has a hemoglobin level <11.0 g/dL (<110 g/L) for males and <10.0 g/dL (<100 g/L) for females. 
3. The subject has a history of any hemoglobinopathy that may affect determination of HbA1c levels.
Additional Criteria That Must Be Met Following Screening and/or Completion of the Pre-Randomization 
Stabilization Period and Prior to Randomization:
1.The subject will be required to have an HbA1c level of â‰¥6.5% to <11.0% if the subject is on metformin alone or â‰¥7.0% 
to <11.0% if the subject is on insulin alone or in combination with metformin. 
2. The subject must not have received any investigational compound within 30 days or 5 half-lives, whichever is 
longer, prior to randomization.
3. The subject must not have received an antidiabetic agent other than metformin or insulin within the 12 weeks 
prior to randomization.
4. The subject must not have received oral or parenteral steroids for more than 3 weeks (cumulatively) within the 
6 months prior to randomization or have received a course of oral or parenteral steroids within the 2 months prior to randomization.
5. The subject has a systolic blood pressure <160 mmHg and a diastolic pressure <100 mmHg. (Antihypertensive 
medications will be allowed during the study).
6. The subject has an alanine aminotransferase (ALT) level <3Ã— upper limit of normal (ULN) or an ALT level 
<5Ã—ULN with a confirmed diagnosis of nonalcoholic fatty liver disease (NAFLD). 
7. The subject does not plan to leave the geographic area within 1 calendar year following randomization. 8. Male or female subjects, 10 to 17 years of age, inclusive, at the time of randomization.
For subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking insulin prior to CCI
Property of Takeda: For Non-Comt Be Mett Be M
ior to Rto 
equired toquired 
ject is onect is o
ust not haust not
r to randto ra
ject mustct mu
totorandorand
he subjeche subj
66momonthnooo
to tora
5.5.Tmmercial Use Only and Subject to the Applicableble
0 countrcounca
n::Ap
aluationuatio
mately 56ately 5
ndomizandomiztt
ssociationciatio
g/dL, ran/dL, ra
GTT] gluGTT] gluS
type 1 dype 1 
l <11.0 <11.0 g
y hemoglhemogseof Useofof
om
pepeble Terms of
Alogliptin
Study No. SYR-322_309 Page 15 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
randomization, the following criteria must also be met: 
9. The subject must have a fasting C-peptide concentration â‰¥0.6 ng/mL ( â‰¥0.20 nmol/L) (drawn at least 1 week after 
treatment for ketosis or acidosis, if applicable).
10. No presence of autoantibodies as documented by glutamic acid decarboxylase [GAD] 65 and islet antigen 
[IA]-2 antibodies below the upper limit of the normal reference ranges at randomization.
11. The subject must have a BMI >85th percentile, documented at randomization.
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is HbA1c change from Baseline at Week 26. 
Secondary endpoints for this study are:
Efficacy
HbA1c change from Baseline at Weeks 12, 18, 39, and 52.
Safety: 
!Physical examination findings. 
!Vital sign measurements.
!12-lead ECG abnormalities. 
!Adverse events (AEs).
!Incidence of infections (Total and urinary and respiratory tract infections) and hypersensitivity reactions.
!Incidence of hypoglycemia.
!Clinical laboratory evaluations (hematology, serum chemistry, and urinalysis). 
!Change from Baseline in biomarkers of bone turnover (bone-sp ecific alkaline phosphatase a nd CTX) at Weeks 26 
and 52.
!Change from Baseline in CD26 surface antigen levels at Weeks 26 and 52.
CCI
Propepel Use Only and Subject to the Applicable Terms of Useofof
ract infecact infe
chemistrchemist
nover (boover (b
ntigen letigen lT
peperty of Takeda: For Non-Commercial
Alogliptin
Study No. SYR-322_309 Page 16 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Statistical Considerations:
The primary efficacy analysis will be conducted using a contrast at Week 26 derived from a mixed model for repeated 
measures (MMRM) with change from Baseline in HbA1c as the response variable, treatment, visit, and visit-by-treatment interaction as fixed categorical effects , and baseline HbA1c and visit-by-baseline HbA1c 
interaction as continuous covariates. 
The secondary efficacy variable will be analyzed using additional contrasts at Weeks 12, 18, 39, and 52 derived from 
the primary analysis model. Continuous exploratory efficacy variables will be analyzed using models similar to the primary analysis model. Categorical variables and time to hyperglycemic rescue will be analyzed using logistic regression models and a Cox regression model, respectively. 
Safety variables will be summarized using descriptive statistics or frequency counts as appropriate.
Sample Size Justification: A total of 75 randomized subjects per treatment group will ensure at least 90% power to 
detect a difference in mean change from Baseline in HbA1c at Week 26 between alogliptin 25 mg QD and placebo assuming a treatment effect of 0.5%, a SD of 0.9%, and a 2-sided false-rejection rate of 5%. CCI
Property of Takeda: For Non-Commercial Use Only and Subject tttt to the Al ensure ensurApplicable Terms of Useted d 
2 derived2 deriv
els similas simi
d using ld using 
propriateropriatofof
ogliptin gliptin
rate of 5rate ofA
tt
Alogliptin
Study No. SYR -322_309 Page 17of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Study -Related Responsibilit ies document. The ident ified vendors in the template for specific 
study -related activit ies will perform  these act ivities in full or in partnership with the sponsor.
3.2 Coordinating Investigator
Takeda will select a Signatory Coordinating Investigator fro m the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  medicat ion, thei r experti se in the therapeutic area and the conduct of clinical 
research as well as study participat ion. The Signatory Coordinat ing Investigator will be required to 
review and sign the clinical study  report and by  doing so agrees that i t accurately  describes the 
resul ts of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 18 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
3.3 List of Abbreviations
ADA American Diabetes Association
AE adverse event
AESI adverse event of special interestALT alanine aminotransferase
AST aspartate aminotransferase
AUC
âˆž area under the concentration-time curve from time 0 to infinity 
AUC 24 area under the plasma concentration-time curve from time 0 to 24 hours
BID twice daily
BMI body mass index
CFR Code of Federal Regulations
Cmax maximum observed plasma concentration
COVID-19 coronavirus disease 2019
CTX C-terminal telopeptide
DKA diabetic ketoacidosis
DMC Data Monitoring Committee
DPP-4 dipeptidyl peptidase-4ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
FAS full analysis setFDA Food and Drug Administration
GAD glutamic acid decarboxylase
GCP Good Clinical Practice
GGT
âˆ€-glutamyl transferase
GLP-1 RA glucagon-like peptide-1 receptor agonist
HbA1c glycosylated hemoglobin
hCG human chorionic gonadotropin
IA islet antigen
ICF informed consent form
ICH International Conference on Harmonisation
ID Identification
IEC independent ethics committee
INR international normalized ratio
IRB institutional review boardCCI
CC
ICCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehoursours
ormorm
ar filtratir filtra
cines Agnes A
setet
d Drug ADrug 
lutamic autamic
Good Good
âˆ€-
ICFCF
ICHICH
ICom
Take
Alogliptin
Study No. SYR-322_309 Page 19 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
ISPAD International Society for Pediatric and Adolescent Diabetes
IVRS interactive voice response system
IWRS interactive web response system
K2EDTA potassium ethylenediamine tetraacetic acid
MMRM mixed model for repeated measures 
MODY maturit y-onset diabetes  of th e young
MTD maximum tolerated dose
NAFLD nonalcoholic fatty liver disease
NOAEL no-observed-adverse-effect level
OGTT oral glucose tolerance test
PD pharmacodynamic(s)
PI Principal Investigator
PIP Paediatric Investigational Plan
PK pharmacokinetic(s)
PPG postprandial glucose 
PPS per protocol set
PTE pretreatment event 
QD once dail y
SAE serious adverse event
SAP statistical analysis plan
SUSAR suspected unexp ected serious adverse reaction
T2DM type 2 diabetes mellitus
TEAE treatment-emergent adverse event
ULN upper limit of normalUS United States
WHO World Health Organization
3.4 Corporate Identification 
TDC Europe Takeda Development Centre Europe Ltd.TDC Americas Takeda Development Center Americas, Inc.
TDC TDC Europe, TDC Americas and/or TDC Asia, as applicableTDC Asia Takeda Development Center Asia Pte. Ltd.
Takeda TDC Europe, TDC Americas and/or TDC Asia as applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplanlan
pected seected 
etes melles me
nt-emergeme
er limit oer limit
Unnited Stited S
WorldWor
orporatrpor
opepe
AmericaAmeric
DCC
TDC ATDC
TakTCCICCI
Alogliptin
Study No. SYR -322_309 Page 20of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
4.0 INTRODUCTION
4.1 Background
Type 2 di abetes m ellitus (T2DM) is a complex metabolic disorder of heterogeneous and 
multifactorial et iology, with a strong hereditary component and genetic predisposit ion overlaid by 
social, behavi oral, and environmental  risk factors [1-9] . Informat ion on the underlying 
mechanisms, the phases of pathogenesis, clinical presentation and course, risk factors, attendant 
complicat ions, and treatment is still co mparat ively sparse for pediat ric populati ons and i s being 
widely debated. Overall, however, the pathophy siology of T2DM in children and adolescents 
appears to be similar to that in adults [
1,6,10-15].
The incidence of T2DM among children and ado lescents i s on the rise, l argely  due to the 
worldwide increase in childhood obesit y. In the US, the SEARCH for Diabetes Youth Study  
reported th e prevalence of T2DM among children and ado lescents (10
-19 years) to be 0.46 cases 
per 1000 in 2009, which is a 35% increase fro m that reported in 2001 [16]. Project ions from  the 
SEARCH study estimate that the number of children and ado lescents with T2DM could quadruple 
over the next 40 y ears [
17].
The gl obal increase in T2DM in children and adolescents has evo lved into an im portant public 
healt h issue [
10,18-20] . T2DM is associated with mult iple long -term com plicat ions leading to 
morbidity as well  as prem ature m ortalit y, including: accel erated development of cardio vascular 
diseases; nephropathy  and ki dney failure; retinopathy  and blindness; nervous system disease 
including peripheral neuropathy; macrovascular complicat ions; high blood pressure; peripheral 
vascular disease and lower limb amputation; non -alcoho lic fatty liver disease, including 
non
-alcoho lic steatohepatit is; and increased risk of death from infect ion such as pneumonia. In 
children and ado lescents, the increased incidence of T2DM and obesit y observed gl obally during 
the past 2 decades not only places a severe burden on the individualâ€™s physical, psycho logical , 
emotional, and soci al well -being, but will also have long -term public healt h and soci etal 
consequences, as these patients are at risk of progressing to the aforement ioned chronic 
complicat ions at a relatively young age and may  experience subsequent loss of their productivit y 
as adults [1,10,12,18,21-26] . In addit ion, the rate s of long-term medication use for treatm ent of the 
diabetes -related complicat ions, of physician contacts, and of hospitalizat ions are likely to increase.
Although a diverse range of oral ant idiabet ic agents are available, few of these have been 
evaluated i n children and ado lescents. Until recent ly, only met formin and insulin were approved in 
the US and Europe for treatment of T2DM in pediatric patients. Liraglut ide, an injectable 
glucagon -like peptide -
1receptor agonist (GLP -1RA), has beco me available for children and 
adolescents aged 10 to 17 y ears wi th T2DM. According to treatment guidelines set forth by  the 
AAP (American Academy of Pediatrics) and the IDF/ISPAD (Internat ional Diabetes 
Federat ion/Internat ional Societ y for Pedi atric and Adol escent Diabetes ), initial care may require 
insulin unt il diagnost ic classificat ion of T2DM has been confirmed and the patient is metabo lically 
stable [27,28] . Once m etabo lically stable, metformin is the init ial pharmaco logic treatm ent of  
choice for children and ado lescents with T2DM. However, both metformin and insulin have 
disadvantages. Metformin must be administered twice daily  (BID), and is commo nly associ ated 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 21of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
with unpleas ant gastrointestinal side effects. Furthermore, most children do not maintain adequate 
glycemic control wit h metformin alo ne for the l ong term . This was recent ly demo nstrated in the 
TODAY (Treatment Options for Ty pe 2 Di abetes in Adolescents and Youth) study that evaluated 
metformin and rosiglitazone vs dietary  modificat ions and exercise alo ne in approximately 700 
pediatric patients with T2DM [29]. The primary outcome of this study  was l oss of  glycemic 
control , defined as a glycated hemoglo
bin level of at least 8% for 6 months or sustain ed metabo lic 
decom pensat ion requiring insulin. Results of this study showed that metformin alo ne was effective 
in maintaining durable glycemic control in only one -half o f the study  parti cipants. This suggests 
that a m ajority of youth wi th T2DM may  requi re combinat ion treatment or insulin therapy wit hin 
just a few years after diagnosis [29].
Treatment with insulin is not ideal for the pediatric populat ion as it has several limitat ions such as 
weight gain and hypoglycemia, and requires mult iple daily  inject ions that can lead to poor 
compliance [30]. Therefore, there is a need to investigate alternat ive oral therapies available for 
children. Having a once daily o ral antidiabet ic agent available as an alternat ive or as add -on to 
metformin or insulin may provide benefit to the patient, potentially for newly diagnosed patients as 
well as for those who cannot tolerate metformin or whose diabetes is not controlled on m etformin 
and/or insulin.
As part of the pediatric program, 2 studi es have been conducted to assess potential aloglipt in 
toxicity in the j uvenile rat. A 4 -week toxicit y study was conducted in male and female rats that 
were 4 weeks of age at init iation of do sing. Because the pivotal toxicit y studi es were conducted 
using rats that were 8 weeks of age at study init iation, this 4 -week study  was conducted to provide 
aloglipt in toxicit y info rmation in t he young rodent through the age of the rats at init iation of d osing 
in the pivotal repeat -dose toxicit y studi es (SYR -
322-00610). To ensure no effect on the 
developing reproductive organs of the juvenile male, a second toxicit y study  was conducted in 
4-week ol d male rats administered aloglipt in for 8 consecut ive weeks (SYR - 322-18040). Doses 
selected for this study  were the same as those used in the pivotal 4 -week toxi city study  in which 
rats were 8 weeks of age at dose init iation. The NOAEL (no -observed -adverse -effect level) in that 
study  was 300 mg/kg/day and produced exposure margins (based on area under the plasma 
concentration -time curve fro m time 0 to 24 hours (AUC 24) that were 53 -to 58 -fold the AUC 24 
measured in adult men and women, respect ively, at the clinical dose of 25 mg/day.
No toxicologically meaningful ef fects were noted in juvenile rats (4 -weeks of age at dose 
initiation) administered aloglipt in daily for 4 consecutive weeks. Similarly, the 8 -week 
repeat -dose toxicity study  in male juvenile rats (4 weeks of age at dose init iation) did not show any 
aloglip tin
-related effects on the developing male reproductive organs. Toxicokinet ic data in the 
juvenile rats were similar to th ose ob tained in adult rats. 
With regard to reproductive toxicit y, alogliptin administered to pregnant rabbits and rats was not 
teratogenic at doses of up to 200 and 500 mg/kg, or 149 and 180 times, respect ively, the mean 
exposure in adults at the 25 mg dose. Addit ionally, doses of al oglipt in up to 250 mg/kg (~ 95 times 
the mean exposure in adults at the 25 mg dose) administered to pregnant rats did not harm the 
developing embryo or adversely  affect growth and development of offspring.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 22of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Aloglipt in has been shown to be safe and effective in the treatment of adults with T2DM in a 
comprehensive clinical program that included 55 clinical studies and invo lved approximately 
1000 healt hy adult subjects and more than 12,000 adult subjects with T2DM. This includes 
phases 1, 2, and 3 controlled an d uncontrolled studies (including those conducted in Japan and 
China).
A total o f 30 phase 1 and 2 clinical pharmaco logy studi es were conducted using single and 
multiple doses of alogliptin 6.25 to 800 mg, in healthy adults, adults with T2DM, adults with r enal 
impairment, and adults with hepat ic impairment.
4.2 Rationale for the Proposed Study
As di scussed above, there is a need for new ant idiabet ic therapies, in addit ion to m etformin and 
insulin, for treatment of T2DM in children.
In accordance with the US FDA Pediatric Research Equi ty Act and the EMA PIP requirements, a 
phase 3 study  is being conducted to invest igate the safet y and efficacy  of aloglipt in in a pediatric 
popul ation with T2DM aged 10 to 17 years, inclusive. The cho ice of the age group is supporte d by 
epidemi ologic data that indicates that T2DM in children and adolescents is most commonly 
diagnosed at the time of pubert y, between approximately 12 and 14 y ears, inclusive. 
A phase 1, pediatric, pharmacokinet ic (PK)/pharmacodynamic (PD) study of alog liptin 
(SYR -322_104) was completed. This study  was conducted to determine the PK and PD profiles, 
safet y, and tol erabili ty of a single dose of aloglipt in 12.5 mg and 25 mg in subjects with T2DM 
between 10 to 17 years old and adult subjects with T2DM. This phase 3 study will  evaluate 
aloglipt in 25 mg since it was determined to be the appropriate dose for pediatric subjects based on 
the resul ts of the phase 1 study  (see Sect ion 6.3for dose sel ection rati onale). 
5.0 STUDY OBJECTIVES AND ENDPOINTS 
5.1 Objectives
5.1.1 Primary Objective
The primary  object ive of this study  will be to evaluate the efficacy of aloglipt in 25 mg QD 
compared to pl acebo when administered as monotherapy, orwhen added onto a background of
metformin alo ne, insulin alone, or a combination of met formin and insulin, as measured by the 
glycosylated hemoglo bin (HbA1c) change fro m Baseline at Week 26 in pediatric subjects with 
T2DM. 
5.1.2 Secondary Objectives 
To evalua te the HbA1c change from Baseline after treatment with aloglipt in as compared with 
placebo at Weeks 12, 18, 39, and 52.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 23 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
To evaluate the safety of alogliptin compared to placebo by assessing: 
!The incidence of hypoglycemic events, treatment emergent adverse events (TEAEs), clinical 
laboratory parameters, electrocardiogram (E CG) readings, physical examinations, and vital 
signs for Weeks 26 and 52.
!The effects on biomarkers of bone t urnover (bone-specific alkaline phosphatase and 
C-terminal telopeptide [CTX]) markers at Weeks 26 and 52. 
!The effects on CD26 surface antigen levels at Weeks 26 and 52.
5.2 Endpoints
5.2.1 Primary Endpoint
HbA1c change from Baseline to Week 26.
5.2.2 Secondary Endpoints
Efficacy
HbA1c change from Baseline at Weeks 12, 18, 39, and 52.
Safety:
!Physical examination findings. 
!Vital sign measurements.CCI
Property of Takeda: For Nontss
rimary rimar
change fchange
.22
EfficacEfficartyplicable Terms of Use
HbHNon-Commercial Use Only and Subject to the Appl
Alogliptin
Study No. SYR-322_309 Page 24 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
!12-lead ECG abnormalities. 
!Adverse events (AEs).
!Incidence of infections (To tal and urinary and respiratory tract infections) and hypersensitivity 
reactions.
!Incidence of hypoglycemia. 
!Clinical laboratory evaluations (hematology , serum chemistry, and urinalysis). 
!Change from Baseline in biomarkers of bone  turnover (bone-specific alkaline phosphatase and 
CTX) at Weeks 26 and 52.
!Change from Baseline in CD26 surface antigen levels at Weeks 26 and 52.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useivitity y
). 
line phone ph
 and 52and 5
roperty of Takeda: For Non-Commercial Use Only and Subject to t
Alogliptin
Study No. SYR -322_309 Page 25of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
6.0 STUDY DESIGN AND DES CRIPTION
6.1 Study Design
This will be a mult icenter, r andomized, double -blind, pl acebo -controlled 52 -week study  
evaluat ing the efficacy and safet y of aloglipt in 25 mg QD compared to placebo, in children and 
adolescents 10 to 17 y ears of age, inclusive, at the time of rando mizat ion, wi th a confirmed 
diagnosis of T2DM and who are experiencing inadequate glycemic control. Subjects who are 
recrui ted for thi s study  shoul d be on a background of met formin alo ne, insulin alo ne, or on a 
combinat ion of metformin and insulin. 
Subjects will enter into a Screening Period of up to 2 weeks. During the Screening Period 
investigators should: 
ï‚·Assess the subjectsâ€™ and their respect ive guardiansâ€™ suitabilit y for the study , in terms of 
study -procedure com pliance and lo ng-term commitm ent.
ï‚·Educate subjects on diet and exercise cons istent with standard of care for T2DM. 
ï‚·Educate subjects on compliance with protocol procedures.
Subjects who have completed all required Screening Procedures, and who meet all entry  criteria 
may proceed to Rando mizat ion/Day 1. Eligible subjects will be ra ndomly assigned in a 1:1 ratio to 
1 of 2 treatment groups, aloglipt in 25 mg QD or matching placebo. 
Subjects who have not met all o f the addit ional randomizat ion criteria listed in 7.3, will be allowed 
to enter a Pre -Randomizat ion Stabilization Period (see Section 6.2).
In addit ion to receivin g doubl e
-blind study  medicati on, subjects will be required to maintain their 
background antidiabetic therapy (if applicable) , at the same dose at Day  1(eg, baseline insulin 
doses, if applicable), throughout the first 26 weeks of the Double -Blind Treatm entPeriod.
Subjects will receive diabetes educat ion and ho me glucose monitoring training during the 
Pre-Rando mizat ion Stabilizat ion Peri od (if applicable) and during the first 26 weeks of the 
Doubl e-Blind Treatm ent Peri od. Subj ects will maintain blood glucos e diaries which will be 
reviewed at each study  visit throughout the study . 
Subjects who complete the 52 -Week double -blind treatment period willcomplete an 
End-of-Treatm ent Visi
t and Foll ow-Up Visi t, 2weeks after the End-of-Treatm ent Visi t. Subj ects 
who terminate doubl e-blind study  drug prem aturely  will complete an End- of-Treatm ent Vi sit and 
Follow-Up Visit, 2 weeks after the End-of-Treatm ent Visit and will cont inue to be fo llowed for the 
52-week duration of the study  and co mplete a projected Week 52 Visi t. 
Subjects who are not eligible for randomization will be referred back to their primary  care 
physician for resumpt ion of their care. 
This study  will be conducted at approximately 60 sites in 20 countries. 
Sites will emplo y all efforts to see subjects in the clinic for assessments. In unavo idable 
circumstances (eg, a widespread disease outbreak such as the COVID -19 pandemic or natural 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 26of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
disaster), except ions may be granted for alternat ive methods for conducting subject visit s with 
approval  by the medical monitor. Such instances will be documented in the study  records. Data 
collected with alternat ive methods may be handled differently in the final data analyses. This will 
be docum ented in the statist ical analysis plan (SAP) .
A schemat ic of the study  design is shown in Figure 6.a. A schedule of assessments is listed in 
Appendix A.
Figure 6.a Schematic of Study Design
ScreeningPre-Randomization
Stabilization
Period (if needed)Double -Blind Treatment Period
Weeks 1 -52 After Randomization (a)End-of-
Treatment 
VisitFollow -Up 
Visit
AssessmentScreening 
Visit (b)Every 
3 Months (b) Week -1Baseline 
Visit
(Day 1)4
(c) 1218 
(d) 2632 
(c) 3945
(c) 52 54 (c)
Visit windows 
(days)(Up to 14 
Days)ï‚±2ï‚±7ï‚±7ï‚±7ï‚±7ï‚±7ï‚±7 ï‚±7 ï‚±2
(a) Subjects who terminate double -blind study drug prematurely will complete an End -of-Treatment Visit and Follow -Up Visit, 2 
weeks after the End-of-Treatment Visit , and will continue to be followed for the 52 -week duration of the study and complete a 
projected Week 52 Visit. 
(b) The Screening Visit will be scheduled within 2 weeks prior to Day 1 or the start of the Pre -Randomization Stabilization Period. 
During the Pre -Randomization Stabilization Period, subjects will visit the study center at regular int ervals according to the 
investigatorâ€™s discretion but at least every 3 months and at Week -1 prior to randomization. 
(c) The Week 4, 32, 45, and 54 visits will be conducted only via telephone call to the subject. 
(d) The Sponsor or its designee will deci de whether the Week 18 Visit will be conducted as an in -clinic visit, or optionally, as a 
home health visit.Alogliptin 25 mg QD
Matching Plac ebo
HbA1c requirement:
â‰¥6.5% to <11.0% if on metformin alone
â‰¥7.0% to <11.0% if on insulin alone or 
in combination with metforminFollow-up 
2 We eksScreenin g
Up to 2 We eks Pre-Random ization
Stabilization Period
If neede dDB Treatmen t 
52 We eks
Day 1
End of 
DB Med sFinal Vis itProcedures
â€¢HbA1c monitoring
â€¢Adhere nce
â€¢Safety Monitoring
â€¢Medi cation adjustmentsEligibility  Assessment
(Secti ons 7.1 and 7.2)Eligibilit y Assessment
(Section s 7.1, 7.2, and 7.3)Wk -1
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 27of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
6.2 Pre-Randomization Stabilization Period (if needed)
Subjects who meet all inclusio n and exclusio n criteria listed in Sect ions 7.1and 7.2, respectively, 
AND who are anticipated to meet the addit ional ent ry criteria listed in Section 7.3following 
medical oversight (ie, washout of prior med ications, adjust ment to their metformin or insulin doses, 
adjustment to antihypertensive regimen) by the investigator will be allowed entry  into the 
Pre-Rando mizat ion Stabilizat ion Peri od.
The Pre -Rando mizat ion Stabilizat ion Peri od is intended to meet the fo llowing obj ectives:
ï‚·Allow a period of wash -out of pri or medicat ions and adjust ment of anti -hypertensive 
treatm ent; 
ï‚·Evaluate underlying etio logy and persistence of elevated alanine aminotransferase (ALT) 
levels;
ï‚·Allow subjects who are on metformin to reach their maximum toler
ated dose (MTD) of 
metformin and maintain that dose for a minimum of 2 months;
ï‚·Allow for subjects to be monitored for deterioration of glycemic control and potential study  
qualificat ion;
ï‚·If considered appropriate, init iate insulin therapy in subjects with HbA1c l evels >11.0% on 
MTD of m etformin alo ne;
ï‚·Allow establishment of a stable insulin regimen for participants entering the 
Pre-Rando mizat ion Stabilizat ion Peri od on insulin;
ï‚·Allow invest igators to intensify or wean insulin therapy as appropriate for the management of 
each individual subject;
ï‚·Subjects treated on insulin should be carefully  monitored wi th a goal  to di scontinue insulin 
therapy  [31]. If the subject is unable to discontinue insul in therapy, the dose of insulin must be 
stable and maintained for 2 months prior to randomizat ion and their HbA1c must be â‰¥7% to be 
eligible to proceed to randomizat ion.
Regardless of part icipation in the Pre -Rando mizat ion Stabilizat ion Peri od, invest igato rs shoul d 
ensure the fo llowing for all subjects: 
ï‚·The study  site staff adequate time to assess the subjectsâ€™ and their respect ive guardiansâ€™ 
suitabili ty for the study , in terms of study -procedure com pliance and l ong-term commi tment;
ï‚·Subjects are encouraged to intensify  dietary  and exerci se regimen; 
ï‚·Subjects are encouraged to be compliant with all aspects of the treatment regimen.
Subjects will return to the clinic for assessments at regul ar intervals during the Pre -Rando mizat ion 
Stabilizat ion Peri od at the invest igatorâ€™s discretion, but at least every 3 months. The duration of 
participat ion in the Pre -Rando mizat ion Stabilizat ion Peri od will vary  for each subject based on 
his/her status.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 28of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
During the Pre -Rando mizat ion Stabilizat ion Period, subjects receiving m etformin will cont inue to 
receive metformin wit h a treatment goal of at least 1000 mg BID or their documented MTD 
without treatm ent-related side effects nor symptoms of ketosis. Subjects who are already receiving 
metformin 1000 mg BID or their MTD will not need to adjust their dose unless side effects 
associ ated wi th metformin, such as gastrointestinal symptoms or other symptoms associated with 
metformin, require a decrease in dose.
In subjects already  receiving insulin alone or insulin in combinat ion with MTD of m etformin, 
insulin doses can be reduced, and insulin can be discontinued in patients who are able to maintain 
HbA1c levels <8.0%. 
Subjects with HbA1c levels >11% on MTD of m etformin alo ne will be allowed to init iate insulin 
therapy  at the discret ion of the invest igator.
Invest igators may intensify or wean insulin therapy as appropriate for the management of each 
individual subject. These subjects should be adequately mo nitored for potential hypo -or 
hyperglycemia. 
Subjects will receive ins ulin wit h the goal of achieving a stable dose required for glycemic contro l 
before proceeding to randomizat ion. A stable dose of insulin is defined as a period of at least 
1month during which an insulin dose change is not required to prevent hy poglycemia or 
symptom atic hyperglycemia.
Once subjects meet the object ives o f the Pre -Randomizat ion Stabilizat ion Peri od, they  will return 
to the clinic (Week -1) to confirm qualificat ion for all inclusio n and exclusio n criteria specified in 
Secti on 7.3. 
6.3 Justification for Study Design, Dose, and Endpoints
The select ion of the aloglipt in 25 mg dose for the proposed phase 3 pediatric study is based on the 
resul tsof the phase 1 PK/PD study (Study SYR -322_104). Following single oral administration of 
aloglipt in 12.5 or 25 mg tablets to children, adolescents and adults wit h T2DM in Study  
SYR -322_104, the PK and PD of alogliptin appeared to be generally similar betwe en the 2 age 
groups of pediatric subjects (10- 13 and 14 -17 years of age, respectively), with dose -proporti onal 
increases in the mean maximum observed plasma concentration (C max) and area under the 
concentration -time curve from time 0 to infinit y (AUC âˆž) values of aloglipt in and higher mean E max
(maximum drug
-induced effect) and AUEC 24 (area under the effect curve fro m 0 to 24 hours) 
values for dipept idyl pept idase -4 (DPP -4) inhibit ion with the 25 m g dose, rel ative to 12.5 mg. 
Com pared to adul t subjects rece iving 25 mg alogliptin, the mean C maxand AUC âˆž values of 
aloglipt in were 54% to 68% lower in pediatric subjects fo llowing a 12.5 mg dose and 23% to 29% 
lower at the 25 m g dose. 
Model -based simulat ions of steady  state exposures following dosing of aloglipt in 12.5 mg and 
25mg in pediatric and adult subjects (n=75 each) were performed, assuming similar distribut ion of 
body  weights between pediatric and adult subjects with T2DM. Based on the PK and PD data and 
model simulati ons, pedi atric subjects wi th T2DM r equire the 25 mg dose of aloglipt in to best 
approach alogliptin exposures and DPP -4 inhibit ion similar to those in adults with T2DM. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 29of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Therefore, the 25 mg dose is proposed for evaluation in the pediatric phase 3 program. The results 
of these studi es are dee med to be adequate to support the safe and effect ive use of alogliptin in a 
pediatric popul ation whose di sease is not adequately  controlled wi th diet and exercise alone or 
with metformin, insulin, or a combinat ion of metformin and insulin. Targeting this p atient 
popul ation is clinically important because this strategy focuses on the medical need to improve 
glycemic control regardless o f current therapy  and is consistent with current pediatric diabetes 
practi ce of aggressively  treating hyperglycemia.
6.4 Prematu re Termination or Suspension of Study or Investigational Site
6.4.1 Criteria for Premature Termination or Suspension of the Study
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early terminat ion of the study .
ï‚·New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participat ing in the study .
ï‚·The independent Data Monitoring Committee (DMC) recommends that the study  shoul d be 
suspended or terminated. 
ï‚·Significant vio lation of GCP that compromises the abilit y to achieve the primary study  
objectives or compromises subj ect safet y.
6.4.2 Criteria for Premature Termination or Suspension of Investigational Sites
A study  site may be terminated prematurely  or suspended if the site (including the Investigator) is 
found in significant vio lation of GCP, protocol, or contractual agreem ent, i s unable to ensure 
adequate performance of the study , or as otherwise permitted by  the contractual  agreem ent.
6.4.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s)
In the event that the sponso r, an inst itutional review board (IRB)/independent ethics committee 
(IEC) or regulatory  authori ty elects to terminate or suspend the study  or the parti cipat ion of an 
investigat ional site, a study -specific procedure for early  terminat ion or suspensio n will be 
provi ded by  the sponsor; the procedure will be fo llowed by applicable invest igational sites during 
the course of terminat ion or study  suspensi on.
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria in Sect ions 7.1and 7.2will need to be confirmed as part of Screening procedures; 
additional criteria will need to be met prior to randomizat ion (refer to Section 7.3).
7.1 Inclusion Criteria
Subject eligibilit y is determined according to the following criteria prior to entry  into the study : 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 30of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
1.A confirmed diagnosis o f T2DM using American Diabetes Association (ADA) and World 
Health Organizat ion (WHO) criteria (laboratory  determinations of FPG >126 m g/dL, random  
glucose >200 m g/dL [ ï‚³11.10 mm ol/L], HbA1c â‰¥6.5%, or 2 -hour oral glucose tolerance test
[OGTT] glucose >200 m g/dL), docum ented in the subjectsâ€™ medical record.
Note: Previous inclusio n criteria numbers 2 through 5 were moved to Section 7.3.
6.The subject is thought to be able to swallow the tablet containing the study  medicat ion.
7.A male subject who is sexually act ive wit h a female partner of childbearing potential* agrees 
to use adequate contraception* from signing of informed consent throughout the duration of 
the study . 
8.A female subject of childbearing potential* who is sexually act ive with a male partner agrees 
to use routinely adequat e contraception* from signing of informed consent throughout the 
durati on of  the study .
*Female subjects of childbearing potential are defined as reaching Tanner 
Stage 3. Definit ionsand acceptable m ethods of contraception are defined in 
Secti on9.1.10 Contraception and Pregnancy Avo idance Procedure and 
reporting responsibilit ies are defined in Sect ion 9.1.11 Pregnancy.
9.The subject and his/her legal representative (ie, parents or legal guardians) are able and willing 
to provi de wri tten inform ed consent/assent.
10.The subject and his/her legal representative (i e, parents or l egal guardians) are capable of 
understanding and complying wit h the protocol requirements, including scheduled clinic 
appoint ments.
11.The subject and his/her legal representative (ie, parents or legal guardians) are able and w illing 
to monitor their own blood glucose concentrations with a ho me glucose monitor and complete 
subject diaries. 
For subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking 
insulin at Screening, addit ional criteria will ne ed to be m et pri or to randomization (refer to 
Secti on7.3).
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study : 
1.The subject is treatment -naÃ¯ve .
2.The subject has a history  of hypersensi tivity or allergy  to al oglipt in, other DPP- 4 inhibitors, 
metformin, insulin, or related c ompounds.
3.The subject has a confirmed diagnosis of type 1 diabetes mellitus or maturit y-onset di abetes of 
the young (MODY). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 31of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
4.The subject has a hemoglo bin level  <11.0 g/dL (<110 g/L) for males and <10.0 g/dL 
(<100 g/L) for females.
5.The subject has a history of any hem oglobinopathy that m ay affect determination o f HbA1c 
levels.
6.The subject has a history  of bariatri c surgery .
7.The subject has a history  of proliferat ive diabet ic retinopathy  within the 6 months prior to 
Screening. 
8.The subject has had an episode of diabetic ketoacidosis (DKA) at any time after diagnosis of 
T2DM. 
9.The subject has a history  of pancreat itis.
10.Serum  creatinine ï‚³1.5 mg/dL for male subjects or ï‚³1.4mg/dL for female subjects, or 
creatinine clearance <60 mL/min based on calculatio n by cent ral lab using the Schwartz 
formula [32] for estimated glo merular filtratio n rate (eGFR) at the Screening Visit.
11.The subject has a documented history  of infect ion with human immunodeficiency  virus or 
chronic act ive viral hepatit is. 
12.The subject has any  unstable endocrine, psychiatric or severe rheumat ic disorder, or major 
illness or debilit y that, in the Invest igatorâ€™s opinio n, prohibit s the subject from being a suitable 
candidate for and/or complet ing the study, or may affect the interpretabilit y of his/her efficacy 
or safet y data.
13.
Female subjects who are pregnant, planning to be come pregnant, or who admit to sexual 
activit y without appropri ate contracepti on. 
14. The subject and/or his/her legal representative (ie, parents or legal guardians) is unable to 
understand verbal or written English, or any other language for which a cert ified translat ion of 
the approved informed consent/assent is available.
15. The subject and/or his/her legal representative (ie, parents or legal guardians) is an immediate 
family member (ie, child or sibling) of a study site emplo yee who is invo lved in the condu ct of 
this study .
7.3 Additional Randomization Criteria That Must Be Met Following Screening and/or 
Completion of the Pre -Randomization Stabilization Period
Subjects m ust m eet the following criteria in order to qualify for randomizat ion:
1. The subject will be re quired to have an HbA1c level of â‰¥6.5% to <11.0% if the subject is on 
metformin alo ne or â‰¥7.0% to <11.0% if the subject is on insulin alo ne or in co mbinat ion with 
metformin. 
2.The subject must not have received any invest igational co mpound within 30 days or
5half-lives, whichever is lo nger, prior to randomization.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 32of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
3.The subject must not have received an ant idiabet ic agent other than met formin or insulin 
within the 12 weeks prior to rando mizat ion.
4.The subject must not have received oral or parenteral steroids for more than 3 weeks 
(cum ulatively) wit hin the 6 months prior to randomizat ion or have received a course of oral or 
parenteral  steroi ds wi thin the 2 months prior to randomizat ion.
5.The subject has a systolic blood pressure <160 mmHg and a diastolic pressur e <100 mmHg. 
(Antihypertensive medicat ions will be allo wed during the study ).
6.The subject has an ALT level <3Ã— upper limit of normal (ULN) or an ALT level <5Ã—ULN wit h 
a confirmed diagnosis o f nonalcoho lic fatty liver disease (NAFLD). (See Appendix Gfor 
diagnosti cs leading to confirmat ion of NAFLD.)
7.The subject does not plan to leave the geographic area within 1 calendar y ear following 
rando mizat ion. 
8.Male or female subjects, 10 to 17 y ears of age, inclusive, at the time of randomizat ion.
For subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking 
insulin prior to randomization, the fo llowing criteria must also be met: 
9.The subject must have a fast ing C -peptide concentration â‰¥0.6 ng/mL (â‰¥0.20 nmo l/L) (drawn at 
least 1 week after treatment for ketosis or acidosis, if applicable).
10.No presence o f autoantibodies as documented by  glutamic acid decarboxylase [GAD] 65 and 
islet ant igen [ IA]-2antibodies below the upper limit of the normal reference ranges at 
rando mizat ion.
11.The subject must have a BMI >85th percent ile, documented at randomizat ion.
7.4 Excluded Medications
During this study , any medicat ions deemed necessa ry for the m anagement of any  AEs m ay be 
given at the discret ion of the Invest igator. However, it is the responsibilit y of the Invest igator to 
ensure that the details regarding the medicat ion are recorded in full in the electronic case report 
form (eCRF).
Treatment with ant idiabeti c agents (including DPP -4 inhibitors or GLP -1RAanalogues) other 
than study  drug, m etformin and insulin is not allo wed wi thin 12 weeks prior to Screening and 
through the complet ion of Week 52/End
-of-Treatment Visit, with the excep tion of  those subjects 
who require hyperglycemic rescue medications. 
Treatment with any invest igational medicat ion is not allowed from 30 days or 5 half -lives prior to 
rando mizat ion through the complet ion of the End- of-Treatm ent procedures. Chronic treatm ent 
with inhaled steroids >1000 mcg QD (or Flovent equivalent) should be avoided fro m 30 days prior 
to randomizat ion through the complet ion of the End- of-Treatment procedures. Chronic treatment 
with oral or parenteral  steroi ds shoul d be avoi ded wi thin 2 m onths prior to randomization and 
through the complet ion of the End- of-Treatm ent procedures. It is anticipated that the acute use of 
steroi ds may be required during the double -blind treatm ent period of the study; this will be allowed, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 33 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
if required for the med ical management of subjects. If a subject requires c hronic use of steroids 
during the study, such cases should be discussed with the Medical Monitor prior to consideration 
of study drug withdrawal. The chronic us e of steroids, however, is discouraged.
Initiation of treatment with an atypical antipsychotic medication following Screening and 
throughout the first 26 weeks of the Double-Blind Treatment Period is not allowed unless 
discussed prior to initiation with the sponsor or designee.
7.5 Diet, Fluid, Activity Control 
Subjects will be instructed on proper nutrition and exercise, how to recognize signs and symptoms 
of hypoglycemia, and the use of a glucometer. Each study center should provide nutritional 
guidance in accordance with its standard of care for subjects with diabetes [33] .
7.6 Criteria for Discontinuation or Withdrawal of a Study Drug
A subjectâ€™s study medication may be temporarily suspended or permanently ceased at any time at 
the discretion of the Investigator. Subjects are free to stop taking study medication at any time 
without prejudice to further treatment. If a subject refuses to return to the clinic for study visits, 
specific study visit procedures per Section 7.7, should be collected via telephone contact reports. If 
the subject refuses telephone contact, follow options as per Section 7.7.
The primary reason for permanent discontinuation of the subject from study medication should be 
recorded in the eCRF using the following categories. For screen failure or Pre-Rando mization 
Stabilization failure subjects, refer to Section 9.1.15.
1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires early 
termination because continued participation imposes an unacceptable risk to the subjectâ€™s 
health, or the sub ject is unwilling to continue because of the PTE or AE.
2. Significant protocol deviation. The discovery post randomization that the subject failed to 
meet protocol entry criteria or did not adhere to protocol requirements, and continued 
participation poses an unacceptable risk to the subjectâ€™s health.
3. Lost-to-follow-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented.
4. Voluntary withdrawal. The subject (or subjectâ€™s legally acceptable representative) wishes to 
withdraw from the study. The reason for withdrawal, if provided, should be recorded in the 
eCRF. If a subject chooses to withdraw from st udy participation due to personal concerns CCI
Property of Takeda: For Non-Commercial Use Only ahdrawahdraw
orarirarilysy
cts are fcts are 
t. If a su. If a
SectionSectio
ontact, fntact,
manent manen
ing the ng the
ubjects,ubject
event (Pvent 
n becaubeca
or the sur the
nificantifican
meet promeet prhe Applicable Terms of Uses 
e signs asigns
proviovide nde n
tes tes [33[3
partipar
3. L3.and Subject to the
Alogliptin
Study No. SYR -322_309 Page 34of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
related to the COVID -19 pandemic (other than a COVID -19-related AE), this should be 
specified as the reason for subject withdrawal in the eCRF.
5.Study  terminat ion. The sponsor, IRB, IEC, or regulatory  agency  terminates the study .
6.Pregnancy. Th e subject is found to be pregnant. 
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion
 9.1.11 .
7.Principal Invest igator (PI) discret ion. Invest igator has determined that the subject should be 
withdrawn from  the study  for reasons other than the above reasons (1- 7). 
8.Other.
Note: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF, including 
unavo idable circumstances (eg, a widespread disease outbreak such as the COVID -19 
pandemic or natural disaster).
Also see Sections
 7.8for liver safety  withdrawal  criteria, 7.9for renal safet y withdrawal  criteria, 
and 7.10 for pancreat itis withdrawal criteri a.
In consultat ion with the Medical Monitor, the Investigator may  cease provi ding study  drug to a 
subject at any  time during the study  when eit her (1) the subject meets the study  drug terminat ion 
criteria described above, or (2) the Invest igator determines discont inuat ion of study  drug is in the 
subjectâ€™s best interest.
Note: The subject will remain in the study to collect informat ion regarding all assessments of study 
endpo ints, unless the subject has explicit ly withdrawn consent, as recorded in the source
docum ents.
7.7 Criteria for Discontinuation or Withdrawal from Study Participation
7.7.1 Voluntary Withdrawal
The subject (or subjectâ€™s legally acceptable representative) may discont inue his or her 
participat ion without giving a reason at any  time during the study .
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an AE 
shoul d not be recorded in the â€œvo luntary withdrawal â€ category ).
The following opti ons shoul d be offered to the subject regarding cont inued participat ion: 
1.Subject discont inues study medicat ion, but continues to participate in study  site visi ts and 
procedures following the protocol specified visit schedule.
2.Subject discont inues study medication and study procedures, however, continues telephone (or 
other communicat ion) contact fo llowing the protocol -specified visit schedule. The Projected 
Week 52 Vi sit shoul d be at the clinic, if at all possible. Concomitant medicat ions, upd ate 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 35of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
contact informat ion, and serious adverse event (SAE) assessments should be collected at each 
telephone visit (or other communication), at a minimum .
3.Indirect Method: Subj ect is not willing to have the PI or staff contact them. However, the 
subject wil l allow the site to contact their Primary  Care Physician/Designated Contact, 
preferably every 2 mo nths and at a minimum at the Projected Week 52 Visit to ensure their 
safet y.
4.No further contact/withdrawal of consent, preferably in writ ing--Subject revokes consent to 
contact them direct ly or their Primary Care Physician/Designated Contact. Vital status will be 
checked using appropriate available informat ion sources such as public records. 
The subjectâ€™s continued level of participat ion should be clearly doc umented and updated in the 
subjectâ€™s source documents. Should a subject no longer wish any further contact, the primary 
criterion for terminat ion must be recorded as well. In addit ion, efforts should be made to perform 
all procedures scheduled for the End -of-Treatm ent Visi t, Telephone Foll ow-up Vi sit, and 
Projected Week 52 Visit.
Discontinued or withdrawn subjects will not be replaced.
7.7.2 Lost -to-Follow -up
Every  effort will be made to ensure that the subject continues to return to the clinic for study visits 
and to avoid â€œLost -to-Follow -upâ€ during the conduct of the study . The study staff should make 
diligent attempts to contact subjects who fail to return for study visits by using public informat ion 
websites, institutional databases, subjectsâ€™ health professio nals, and any  other m eans that com ply 
with country , state, and l ocal laws and regulat ions. At a minimum, after the first missed visit, 
subjects who are considered temporarily Lost -to-Follow -up will have at least 2 documented 
telephone contact attempts and 1 certified letter in an effort to contact subjects . Thereafter, every  
2months, and at the end of the study , attem pts will be m ade to determine the health status of 
temporarily Lost -to-Follow -up subj ects. 
The Investigator must attempt to document assessm ents of study  endpoints and occurrence of 
events through the Projected Week 52 Visit. At randomizat ion, all subjects will be asked to 
provi de all (wi thin l ocal legal limit s) contact details, which may include, but is not limited to, 
acceptable representati ve(s), address(es), phone number(s), email address(es), government issued 
ident ificat ion, health insurance provider, relat ives, other contacts, such as primary care physician, 
or other healt h care provider to ensure final fo llow-up. At each study  visit, su bjects should be 
asked about any  updates to thei r contact details. 
If unknown, the subjectâ€™s status should be obtained fro m a reliable contact at approximately 6 
months after subject discont inued drug (if applicable) and at the Projected Week 52 Visit, ei ther by 
speaking with the subject or someone who has knowledge o f the subjectâ€™s vital status or by  
docum ented source (eg, l ab reports, m edical visit records).
In regi ons where allowed by local law, subject locator services may  be used to help ascertain the
healt h status of subjects believed to be Lost -to-Follow-up. If contact is made wit h the subject at 
any step in this process, the subjectâ€™s preferred method of cont inued participat ion in the trial 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 36of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
shoul d be determined and documented in the subjectâ€™s source and updated in electronic data 
capture, as appropriate .
Only just prior to the end of the study , and after the above attempts have been exhausted, will a 
subject be considered officially Lost -to-Follow-Up. If  subject vi tal status i s known at the end of 
the study , the subject will not be considered Lost- to-Follow-up.
7.8 Liver Safety Monitoring and Withdrawal Criteria
7.8.1 Liver Function Test Monitoring
Liver function will be carefully mo nitored throughout the study . Addi tional monitoring m ay be 
necessary  and is recommended for subjects with abnormal liver funct ion tests.
If subjects with normal baseline ALT or aspartate aminotransferase (AST) levels experience ALT 
or AST >3Ã— ULN, follow -up laboratory  tests (at a minimum, serum alkaline phosphatase, ALT, 
AST, tota l bilirubin, ï§-glutamyl  transf erase (GGT), and internat ional norm alized rati o [INR]) 
shoul d be repeated wi thin a m aximum  of 7 days and preferably  within 48 to 72 hours after the 
abnorm ality was f ound.
If subjects with elevated baseline ALT or AST levels ex perience ALT or AST >5Ã— ULN and 
2-fold increases above baseline, fo llow -up laboratory  tests (at a minimum, serum alkaline 
phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be repeated within a maximum of 
7 day s and preferably  within 48 to 72 hou rs after the abnormalit y was found.
If subjects with eit her a normal or elevated baseline ALT or AST levels experience ALT or AST 
>8Ã— ULN, fo llow-up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, AST, total 
bilirubin, GGT, and INR) should be repeated within a maximum o f 48 hours after the abnormalit y 
was found.
7.8.2 Considerations for Temporary Discontinuation of Study Drug
If the ALT or AST levels remain elevated >3Ã— ULN in subjects with normal baseline ALT or AST 
levels ORif the ALT or AST l evels remain elevated >5Ã— ULN and a 2- fold increase above 
baseline occurs in subjects with elevated baseline ALT or AST levels on 2 consecut ive occasions, 
the invest igator must contact the Medical Monitor to discuss addit ional testing, recommended 
monitoring, possible temporary  discont inuat ion of study medicat ion, and possible alternat ive 
etiologies. 
The abnormalit y shoul d be recorded as an AE (please refer to Section 10.2.3 Reporti ng of 
Abnorm al Liver Funct ion Tests for reporting requirements).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 37of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
7.8.3 Permanent Discontinuation of Study Drug
If the fo llowing circumstances occur at any t ime during treatment, the study medicat ion should be 
perm anent ly discont inued:
Subject Baseline Aminotransferases Criteria for Discontinuation of Study Medication
Normal o r Elevated ALT or AST (all subjects) ï‚·ALT or AST >8 Ã— ULN 
Normal ALT and AST ï‚·ALT or AST >5 Ã— ULN and persists for more than 2 weeks
ï‚·ALT or AST > 3 Ã— ULN in conjunction with elevated total 
bilirubin >2 Ã— ULN orINR >1.5
ï‚·ALT or AST >3 Ã— ULN with appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, 
rash and/o r eosinophilia (>5%)
Elevated ALT or AST ï‚·ALT or AST > 5 Ã— ULN AND 2-fold increases above 
baseline values and persists for more than 2 weeks
ï‚·ALT or AST >5Ã— ULN AND 2-fold increases above 
baseline values in conjunction with elevated total bilirubin 
>2 ULN or INR >1.5
ï‚·ALT or AST >5 Ã— ULN AND 2-fold increases above 
baseline values with appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, 
rash and/o r eosinophilia (>5%)
In each of these instances, appropriate clinical fo llow-up should be inst ituted (including repeat 
laboratory  tests) until  a sat isfactory  conclusio n (ie, until the AE reso lves, the laboratory value 
returns to Baseline, or the condition beco mes stable).
If a subject meets the liver safet y criteria and must be discont inued fro m study  medication, the 
subject will continue to be fo llowed per the protocol schedule unt il the study is completed. If the 
subject refuses to return for the study  visits, tel ephone visits may  be conducted; however, this is 
not preferred nor recommended. The reason f or discontinuat ion of study  medicati on shoul d be 
listed as an AE.
If any o f the above ci rcumstances occur at any  time during the study , the abnorm ality should be 
docum ented as an AE, and a Liver Funct ion Test Increase form com pleted. 
The Investigator must complete the AE/SAE eCRF page. If the event meets serious criteria, the 
SAE eCRF page must be co mpleted and an SAE Fax Notification form must be sent to the sponsor 
or sponsorâ€™s designee wit hin 1 working day o f the repeat l aboratory  test.
7.8.4 Re-initiation of Study Drug
If the study  medicati on is discontinued due to any  of the scenarios provided above, study  
medicat ion must not be re -initiated without consultation with the Medical Monitor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 38of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
7.9 Renal Safety Withdrawal Criteria
If a subject does not have renal impai rment at Screening or randomizat ion, but later develops rena l 
impairment that is confirmed by a repeat test within a maximum o f 7 days by the central laboratory 
AND a creatinine clearance <60 mL/min (ut ilizing the Schwartz formula, and based on a 
calculat ion by  the central  laboratory ), the subject will discont inue study  medicat ion after
consultation wit h the Medical Monitor. The central laboratory  will calculate these values at the 
same visit s where a full laboratory  panel  is performed. If a subjectâ€™s calcu lated creatinine 
clearance indicates moderate or severe renal impairment, a laboratory alert will occur to notify the 
site to discont inue the double -blind study  medicat ion.
If a subject discont inues double -blind study  medicati on according to the Renal Safe ty Withdrawal 
Criteria, the event should be recorded as an AE and the reasons for study  drug discont inuat ion 
must be recorded as an AE. The subject will be required to return for protocol study  visit s and 
procedures.
7.10 Pancreatitis Monitoring and Withdrawal Criteria
All subjects will be carefully  monitored f or pancreati tis during the study . Invest igators will urge 
subjects to immediately  call the study  staff if the subject experiences persistent nausea and/or 
vomiting for â‰¥3 days, with or without abdominal pa in.
Blood samples for analysis o f serum amylase and lipase by a central laboratory should be obtained 
at the visit, and other addit ional invest igations should be performed in order to establish diagnosis.
Study  drug shoul d be interrupted immediately  if any of the f ollowing ci rcumstances occur at any  
time during treatment:
ï‚·If pancreat itis is suspected, or
ï‚·Serum  amylase â‰¥2 Ã— ULN, or
ï‚·Serum  lipase â‰¥2 Ã— ULN.
The pancreatic enzyme tests should be repeated within 7 day s after the first sample (with both 
samples an alyzed by the central laboratory), and appropriate imaging tests (as per standard of care) 
shoul d be perform ed to establish diagnosis. The results of these tests should be recorded in the 
source documents.
All subjects wi th elevated pancreat ic enzymes that meet the above criteria should be kept under 
observat ion with multiple serum  amylase and lipase tests to be followed -up unt il reso lution.
If pancreat itis is confirmed, the study  drug shoul d not be restarted.
If any o f the circumstances described above occ ur during the study , the event shoul d be recorded 
as an AE. A Pancreat ic AE of Special I nterest Form must be completed. If the event meets the SAE 
criteria, an SAE Fax Notificat ion form must be sent to the sponsor or sponsorâ€™s representative 
within 1 worki ng day of the repeat laboratory  test.
If a subject discont inues double -blind study  medicati on according to the Pancreat itis Monitoring 
and Wit hdrawal Criteria, the event should be recorded as an AE and the reason for withdrawal 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 39of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
shoul d be documented as an A E. The subject will be required to return for protocol study visit s and 
procedures.
7.11 Procedures for Discontinuation or Withdrawal of a Subject
The Invest igator may discont inue a subjectâ€™s study participat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section 7.6. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any time during the study . Shoul d a 
subjectâ€™s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the Invest igator. In addition, efforts should be made to perform all procedures scheduled for the 
End-of-Treatm ent Vis it. Wit hdrawn subjects will continue to the Week 52/End -of-Treatment 
assessments fo llowed by the Week 54/Fo llow-up tel ephone call. The Week 54/Follow -Up Visi t 
assessments will be completed 2 weeks fo llowing the Week 52/End -of-Treatment Vi sit 
assessments.
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT
This sect ion contains informat ion regarding all medicat ion and m aterials provi ded di rectly by the 
sponsor, and/or sourced by  other m eans, that are requi red by the study  protocol , including 
important sections describing the management of clinical trial material.
8.1 Study Medication and Materials 
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s protocol , the term  study  medicat ion refers to all or any  of the drugs defined below:
Aloglipt in benzoate 25 mg tablet or matching placebo.
Subjects should be instructed to take one tablet daily at the same t ime with or without food.
8.1.1.1 Investigational Drug
Alogliptin benzoate or matching placebo tablets
Aloglipt in benzoate tablets are manufactured by  Takeda Pharmaceut icals and are composed of 
25mg aloglipt in drug substance and excipients; the matching placebo tablets consist of excipients 
only. Alogliptin or pl acebo tabl ets will  be provi ded in 35 count hi gh-densit y polyethylene bottl es
with a child resistance cap. Tablets are oval biconvex light red, film coated with no markings. 
Bottl es will  bear a blinded single panel or booklet label containing medication ID, pertinent 
protocol  inform ation and required caution statements.
8.1.1.2 Companion M edication
Metformin HCl and/or insulin will be prescribed to subjects on background ant idiabet ic therapy 
during the double -blind period of the study . 
Insulin: Subjects will continue to receive insulin wit h the goal of achieving a stable dose required 
for glycemic control dependent on the subjectâ€™s requirements, at the Investigatorâ€™s discret ion.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 40of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Metformin: Subjects will receive met formin with the goal  of being treated with at least 1000 mg 
BID or thei r docum ented MTD.
8.1.1.3 Sponsor -Supplied Drug
Sponsor -supplied drugs referenced in other sections of the protocol include the following:
Aloglipt in benzoate and matching placebo tablets.
8.1.1.4 Rescue Medications 
Subjects who meet protocol -defined hyperglycemia rescue criteria will be rescued wit h an 
antidiabet ic regimen at the Invest igatorâ€™s discret ion as per Section 9.1.17.3 : Criteria for 
Hyperglycemia Rescue. 
8.1.2 Storage
Invest igational drug must be kept in an appropriate, limit ed-access, secure pl ace unt il it is used or 
returned to the sponsor or designee for destruction. Invest igational drug must be stored under the 
condi tions specified on the label (25Â°C [77Â°F] excursions permitted to 15Â°C to 30Â°C [59Â°F to 
86Â°F]), and remain in the original  container unt il dispensed. A daily temperature log of the drug 
storage area must be maintained every  working day .
8.1.3 Dose and Regimen
Table 8.a Dose and Regimen
Treatment Group Dose Treatment Description
Active Placebo
A placebo QD 0 active tablets 1 placebo for 25 mg tablet
B alogliptin 25 mg QD 1 alogliptin 25 mg tablet 0 placebo tablets
Dose interruptions are acceptable based on medical need. The sponsor or designee must be notified 
and consulted for any  dose interrupti ons l onger than 14 continuous days.
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of invest igational drug, 
to or by a study subject, at a dose above that which is assigned to that in dividual subject according 
to the study  protocol .
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdo se without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on AE eCRF(s) according to Section 10.0, Pretreatm ent 
Events and Adverse Events.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 41of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
The SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on 10.2.2 , Collect ion and Reporting of SAEs.
In the event of drug overdose, the subject should be treated symptomat ically.
8.2 Investigational Drug Assignment and Dispensing Procedures
The Investigator or Invest igatorâ€™s designee will access the interactive vo ice response system/ 
interact ive web response system (IVRS/IWRS) at Screening to obtain the subject study number. 
The Investigator or the Invest igatorâ€™s designee will utilize the IVRS/IWRS to randomize the 
subject into the study . During this contact, the Inves tigator or desi gnee will  provide the necessary  
subject -ident ifying informat ion, including the subject number assigned at screening. The 
medicat ion ID number of the invest igational drug to be dispensed will then be provided by  the 
IVRS/IWRS. If sponsor -supp lied drug (aloglipt in 25 mg or matching placebo) is lost or damaged, 
the site can request a replacement fro m IVRS/IWRS. (Refer to the IVRS/IWRS manual provided 
separately .) At subsequent drug -dispensing visit s, the Invest igator or designee will again conta ct 
the IVRS/IWRS to request addit ional invest igational drug for a subject.
Subjects will be dispensed blinded study drug at Day 1, and Weeks 12, 26, and 39. Subjects will be
dispensed sufficient bottles for the visit interval. Subjects will be instructed to take their blinded 
study  drug QD wit h or without food and to return their study drug bottles whether empty or full at  
each visit.
On occasion in unavoidable circumstances (eg, a widespread disease outbreak such as the 
COVID -19 pandemic or natural disaste r), addit ional drug supply may  be provi ded to subjects 
(either at an in -person visit or delivered to the subjectâ€™s residence) to cover extended periods 
between onsite visit s. Any  addi tional resupply  must be reviewed and approved in advance by  the 
sponsor o r designee.
8.3 Randomization Code Creation and Storage
On Study  Day 1, qualified subjects will be randomized to 1 of the 2 treatment groups using the 
IVRS/IWRS. 
8.4 Investigational Drug Blind Maintenance
The invest igational drug blind will be maintained using the IVRS/IWRS.
8.5 Unblinding Procedure 
The invest igational drug blind shall not be broken by the Invest igator unless informat ion 
concerning the investigational drug is necessary  for the m edical treatm ent of  the subject. In the 
event of a medical emergency , if possible, the m edical m onitor shoul d be contacted before the 
investigat ional drug blind is broken to discuss the need for unblinding.
For unblinding a subject, the invest igational drug blind can be obtained by the Invest igator, by 
accessing the IVRS/IWRS.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 42of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
The sponsor must be notified as soon as possible if the investigational drug blind is broken. The 
date, time, and reason the blind is broken must be recorded in the source documents and the same 
inform ation (except the time) must be recorded on the eCRF.
If any site personnel are unblinded, invest igational drug m ust be stopped immediately, and the 
subject must be withdrawn fro m the study . 
8.6 Accountability and Destruction of Sponsor- Supplied Dr ugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee.
The Invest igator or designee must ensure that the sponsor -supplied drug is used in accordance wit h 
the protocol and is dispensed only to subjects enrolled in the study . To docum ent appropri ate use 
of sponsor -supplied drug, the Invest igator or designee must maintain records of all 
sponsor -supplied drug delivery to the site, site inventory, dispensat ion and use by each subject, and 
return to the spon sor or desi gnee.
Upon receipt of sponsor -supplied drug, the Invest igator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and the 
medicat ion is in good condit ion. If quantity and condit ions are acceptable, Invest igator or designee 
shoul d acknowl edge the recei pt of the shipment by recording in IWRS. If there are any  
discrepancies between the packing list versus the actual product received, Takeda or designee 
must be conta cted to resolve the issue. The packing list should be filed in the Invest igatorâ€™s 
essent ial docum ent file.
The Investigator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her entire partici pation in the study . Proper drug 
accountabilit y includes, but is not limit ed to:
ï‚·Frequent ly verifying that actual inventory  matches docum ented inventory .
ï‚·Verifying that all containers used are documented accurately on the log.
ï‚·Verifying that required field s are com pleted accurately  and legibly .
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IVRS/IWRS will include all required information as a separate entry for each subject to who m 
sponsor -supplied dr ug is dispensed.
The Investigator or designee must record the current inventory  of all sponsor -supplied drugs on a 
sponsor -approved drug accountabilit y log. The fo llowing informat ion will be recorded at a 
minimum: protocol number and tit le, name of Investi gator, si te identifier and number, descript ion 
of sponsor -supplied drugs, date and amount dispensed including init ials or signature of the person 
dispensing the drug, and the date and amount returned to the site by  the subject, including the 
initials or si gnature of the person receiving the sponsor- supplied drug. The log should include all 
requi red inform ation as a separate entry  for each subject to whom sponsor -supplied drug is 
dispensed. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 43of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
All study  drug that was not returned to the site by  a subject m ust be invest igated by the site and 
appropriately  docum ented on the drug accoun tability  log.
Prior to si te closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied 
drugs are returned to the sponsor or its designee for destruction. The Invest igator or designee will 
retain a copy  of the docum entati on regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and originals wil l be sent to the sponsor or designee.
9.0 STUDY PLAN
9.1 Study Procedures
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same Investigator or site personnel whenever possible. T he 
Schedule of Study  Procedures i s located in Appendix A. 
9.1.1 Alternative Approaches to Study Procedures and Data Collection Due to 
Unavoidable Circumstances
In unavo idable circumstances (eg, a widespread disease outbreak such as the COVID -19 pandemic 
or natural disaster) that impact the study siteâ€™s ability to conduct study procedures according to the 
Schedule of Study  Procedures ( Appendix A), contingency measures may be implemented. In 
acknowledgement of study  site, hospi tal, local, state, and nat ional restrict ions established in 
response to unavo idable circumstances, the fo llowing measures are being taken for the current 
study :
ï‚·For subjects active in the study , all attem pts shoul d be m ade to perform  the assessments 
with the subject present at the site using the visit windows. Exceptions may be granted for 
alternat ive approaches to study  procedures and data collect ion through approval by the 
sponsor or designee. Such instances must be documented in the study  records and m ay 
include the fo llowing:
â€“Sites im pacted by  unavoi dable ci rcumstances m ust contact the sponsor or designee to 
discuss individual subject and site circumstances to obtain approval for use of 
alternat
ive approaches to study  procedures and data collect ion.
â€“Sites m ay seek approval fro m the sponsor or designee to continue subjects in the stud y 
despite departures from the S chedule o f Study  Procedures. The principal invest igator is 
expected to evaluate the impact to the safet y of the study participants and site personne l 
for subjects to continue. In evaluat ing such requests, the sponsor or designee will give 
the highest prior ity to the safet y and welfare of the subjects. Subjects must be willing 
and able to continue taking study  medicat ion and rem ain com pliant wi th the protocol . 
â€“Other than the End -of-Treatm ent Vi sit, alternat ive methods for conducting subject 
visits (eg, vi deo conferencing, telephone visit s, or in -home study  visit s conducted by  
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 44of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
study  site personnel or desi gnated m edical personnel, contingent upon local 
regul ations) may be used per approval by the sponsor or designee: 
ï‚§Under these circumstances, collect ion of c ertain study  assessments may  be 
omitted and visit windows may  be extended. 
ï‚§When approval is given for a subject to miss an in -person study  visit, a study  
site physician or other qualified site personnel will speak di rectly wit h the 
subject by  telephone or other m edium  (eg, a com puter -based video 
communicat ion) during each visit window to assess subject safety  and overall 
clinical status. 
ï‚§The study  site physician or other qualified site personnel should conduct the 
following assessments within specified -visit window timeframes: AE 
assessments, documentation of conco mitant m edicati on, review of diaries and 
glucometer readings, and drug accountabilit yand an assessment of clinical 
symptoms.
ï‚§Hom e nurses or other qualified clinical personnel may be deplo yed at the 
request of the site, when appropriate. Advance approval from the sponsor or 
designee should be obtained.
ï‚§Other study  assessments may be co llected using an alternative method as 
feasible, and may invo lve audio or video recording where allowed by local 
regul ation. This will be documented in the study  records.
ï‚§In some instances, sites may need to split visit s or sites may only be able to 
perform  a few procedures on site and so me procedures may need to be 
perform ed remotely. Sites should inform sponsor or designee when this occurs.
ï‚§Sites m ay seek approval to extend a visit window in order to conduct an on -site 
visit. Assessments that cannot be completed during the protocol -specified 
window or within the visit window granted by  the sponsor or designee will be 
considered missing data and such departures will be recorded in the study  
records. 
â€“Study  site personnel  may dispense addit ional IP to subjects at a visit to allow for 
potenti ally longer intervals between visit s than originally planned per protocol, or IP 
may be supplied to subjects via delivery  by site personnel  or by  courier.
â€“The End -of-Treatm ent Vi sit shoul d be performed in person. When it is not possible for 
the subject to come to the study site and the protocol -specified visit window cannot be 
exten ded further, the preferred alternat ive for the visit is for qualified study  site 
personnel or designated clinical personnel to go to the subjectâ€™s residence and conduct 
the protocol -specified procedures in that location. Assessments collected at a subjectâ€™ s 
residence should co mply with applicable local regulat ions. If neit her option is available 
with sponsor or designee approval, sites may conduct end -of-treatment procedures 
remotely  as is f easible.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 45of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
All subject discont inuat ions and alternat ive approaches to study procedures (ie, procedures not 
conducted per the Schedule of Study  Procedures) due to unavo idable circumstances (eg, a 
widespread di sease outbreak such as the COVID -19 pandemic or natural disaster) must be 
docum ented in the study  records. Data colle cted using alternat ive methods m ay be handled 
different ly in the final data analyses. This will be documented in the SAP.
9.1.2 Informed Consent Procedure
The requi rements of the informed consent are described in Sect ion 15.2. Informed consent from 
the subjectâ€™s legal representative (ie, parents or legal guardians) and assent, as appropriate, must be 
obtained prior to the subject entering into the study, and before any protocol -directed procedures 
are perform ed.
A unique subject ident ificat ion number (subject number) will be assigned to each subject at the 
time that informed consent is obtained; this subject number will be used throughout the study .
9.1.2.1 Pharmacoge nomic Informed Consent Procedure
As of the date of this amendment, a suffic ient number of samples have been collected and no more 
are needed; therefore, pharmacogeno mic samples no longer need be taken.
Under previous versio ns of this protocol, t he participat ion of study  subjects and study  sites in the 
collect ion of pharmacogeno mic sample(s) wasoptional  and only to be performed in selected 
countri es/sites where approved. A separate informed consent/assent form pertaining to storage of 
the sam ple(s) must have been obtained pri or to collect ing a blood and/or saliva sample for 
Pharmacogeno mic Research for this study. The provisio n of consent/assent to collect and analyze 
the pharmacogeno mic sample is independent of consent to the other aspects of the study .
9.1.3 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth or age, sex, Hispanic ethnicit y 
(US only) and race as described by  the subject of the subject at Screening. Medical hi story  to be 
obtained will include determining whether the subject has any significant condit ions or di seases 
relevant to the disease under study that stopped at or prior to signing of informed consent. Ongoing 
condi tions are considered concurrent medical c ondit ions (see Sect ion9.1.8 ).
Medicat ion history  informat ion to be obtained includes any medicat ion relevant to eligibilit y 
criteria and efficacy/safet y evaluat ion stopped at or within 12 weeks prior to signing of informed 
consent.
9.1.4 Physical Examination Procedure
A baseline, complete physical examinat ion (defined as the assessment prior to first dose of 
investigat ional drug) will consist of the following body  systems: (1) ey es; (2) ears, nose, throat; 
(3)cardiovascular system; (4) respi ratory  system; (5) gastrointest inal system; (6) dermatologic 
system; (7) extremit ies; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and 
(11)other. All subsequent physical examinat ions should assess clinically significant changes fro m 
the assessment prior to the first dose examinat ion. The brief physical exam will consist of the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 46of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
following body  systems: (1) respiratory  system; (2) cardi ovascu lar system; (3) nervous system 
(4)dermatologic system; and (5) gastrointestinal system. The brief and complete physical exams 
will be performed as indicated in Appendix A.
Assessment of pubertal development in bo ys and in girls will be conducted at the Day 1, Week 26, 
and Week 52 Visits. Tanner Stage scoring [34,35] will be assessed at the visits as per  Appendix A. 
An examinat ion to assess Tanner Stage scoring is preferred, but subject -reported scoring (using 
diagrams) is acceptable.
Tanner stage for breast development in girls, genit al devel opment in boy s and pubic hair for both 
sexes should be evaluated. Sites should enter the numerical stage for each of the 2 categories on the 
eCRF for either bo ys or girls.
For girls, ag e of onset of menarche will be co llected at the Day 1 visit and if menarche had not yet 
occurred, this will be verified at each study  visit.
9.1.5 Weight, Height and BMI
The subject should have weight and height measured using a stadio meter (or equivalent) and s cale 
while wearing indoor clothing and with shoes off. 
BMI will be calculated by the site prior to rando mization using the fo llowing form ulaand Centers 
for Disease Control and Prevent ion 3rd to 97th Percent ile growth charts to determine BMI -for-age 
perce ntiles (http://www.cdc.gov/growthcharts/clinical_charts.htm#Set2).
BMI = wei ght (kg)/height (m)2
The values should be reported to 2 decimal places by rounding. The BMI at all other visits and 
BMI Z -scores will be calculated by the Sponsor or designee.
9.1.6 Vital Sign Procedure
Vital signs will include body  temperature (oral  or tympanic measurement), respiratory  rate, bl ood 
pressure (resting more than 5 minutes), and pulse (beats per minute).
When vital signs are scheduled at the same t ime as blood draws, the blo od draw will take priorit y 
and vital signs will be obtained wit hin 0.5 hour before or after the scheduled blood draw.
9.1.7 Documentation of Concomitant Medications
Concomitant medicat ion is any drug given in addit ion to the study  medicati on. These m ay be 
prescr ibed by a physician or obtained by the subject over the counter. Concomitant medicat ion is 
not provi ded by  Takeda. At each study  visit, subjects will be asked whether they  have taken any 
medicat ion other than the study  medicat ion (used from  signing of info rmed consent through the 
end of the study), and all medicat ion including vitamin supplements, over-the-counter medicat ions, 
and oral herbal preparat ions, m ust be recorded in the eCRF.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 47of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
9.1.8 Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condit ions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory , ECG, or phy sical 
examinat ion abnormalit ies noted at the Screening examinat ion. The condit ion (ie, diagnosis) 
shoul d be described.
9.1.8.1 Annual Ophthalmologic Examination
Annual dilated and co mprehensive eye examinat ions are recommended for all subjects [36]. 
Results of the annual ophthalmo logic examinat ion prior to parti cipat ion and during the course of 
the study  shoul d be reviewed by  the Invest igator. Any rele vant medical history  and AEs result ing 
from the annual  exam shoul d be reported on the eCRF.
9.1.9 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptable laboratory procedures. The maximu m 
volume o f blood at any sin gle visit is approximately 24.5 mL, and the approximate total vo lume o f 
blood for the study is 102 mL. Please refer to
 Table 9.aand  Appendix Aon timing of co llection for 
clinical laboratory  testing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 48 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Table 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis (a) 
White blood cell count with autodifferentialPlatelet countHemoglobinHematocritRed blood cell countMean corpuscular volumeMean corpuscular hemoglobin Mean corpuscular hemoglobin concentrationAlbumin
Alkaline phosphataseAlanine aminotransferaseAspartate aminotransferaseBlood urea nitrogenBicarbonateCalciumMagnesiumChlorideCreatinineLactate dehydrogenasePhosphorus
Potassium
SodiumTotal bilirubinDirect bilirubin (only if Total bilirubin is elevated)Total proteinUric acidGGT Lipid panel (total cholesterol, high-density lipoproteins, low-density lipoproteins (direct), 
and triglycerides) (c)
Serum amylase (d)Serum lipase (d)GlucoseQualitative:
AppearanceColorpHSpecific gravityKetonesProtein (albumin)GlucoseNitriteUrobilinogenBlood
Quantitative: (e)
AlbuminCreatinineAlbumin/creatinine ratio 
Other
HbA1cCD26 surface antigenBone specific alkaline phosphataseCTX 
Diagnostic Screening:
Serum Urine
C-peptide (f) 
hCG (female subjects) (g)
eGFR (h)
2-hour postprandial glucose (i)
GAD 65 (f)
IA-2 (f)hCG 
(female subjects) (g)
hCG=human chorionic gonadotropin.
(a) It is recommended that a follow-up urine culture be obtained within 7 days of clinical recovery from all urinary 
tract infections.
(b) Collected only from those subjects who arrive at the clinic in a fasted state. Always drawn in a separate tube for this 
study.
(c) Collect only at the visits specified in Appendix A.
(d) Serum amylase and serum lipase to be performed at Day 1 (Baseline Visit) for all subjects and at an Unscheduled 
Visit for any subject who experiences persistent nausea and/or vomiting for â‰¥3 days with or without abdominal pain.CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef
f Total f Total 
)
nel (total(to
density lidensity
w-densitydensi
and trigland tr
SerumSeru
SerSbumin)umin)
e
obilinogobilino
Bloodlood
QuanQu
Ao
m
Co
g)g)
andial glndial 
D 65 (f)D 65 (f)
-2 (f)2 (f)n
hCG=hhCG
(a) (a
tyoTak
Alogliptin
Study No. SYR-322_309 Page 49 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Table 9.a Clinical Laboratory Tests
(e) The Week 26 urinalysis will only include quantitative assessments. 
(f) Collected once prior to randomization only in subjects who have had the diagnosis of T2DM for less than 1 year 
and/or who are taking insulin. 
(g) To be completed on all female subjects. If a urine pregnancy test yields a positive result, a serum pregnancy test 
must also be collected at the same visit and submitted to the central laboratory for confirmation of results.
(h) Calculated at Screening and Baseline and at Weeks 26 and 52 by the central laboratory using the Schwartz formula.
(i) Select sites only. See section 9.1.9.1 for additional information.
(j) Collected at Baseline and at Weeks 26 and 52. 
The central laboratory will perform laboratory tests  for hematology, serum chemistries, and 
urinalyses. The results of laboratory tests will be returned to the Investigator, who is responsible 
for reviewing and filing these results.
In unavoidable circumstances (eg, a widespread disease outbreak such as the COVID-19 pandemic 
or natural disaster), sites may elect to use local laboratories per approval by the sponsor or 
designee.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyear ar 
nancy tenancy 
ults.ts.
Schwartzchwarf
m chemchemm
igator, igator
k such asuch
per apprer app
operty of Takeda: For Non-Commercial Use Only and S
Alogliptin
Study No. SYR-322_309 Page 50 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
9.1.10 Contraception and Pregnancy Avoidance Procedure
This protocol does not condone or endorse under-age sexual activity. Female participants will be 
asked to use contraception if they are going to be sexually active. Age appropriate contraceptive 
pill or condom plus spermicide are advised. It is noted that Investigators will neither prescribe 
contraceptives, nor provide contraceptive advice beyond the protocol requirements; subjects must 
take responsibility for obtaining advice from the appropriate family doctor or family planning 
provider and preferably after discussion with their parents/legal guardians. Contraception use must 
be practiced if sexually active, from the date of the Screening Visit until the last dose of study
medication intake. Parents/legal guardians and the subject will be advised of this during the 
informed c onsent and assent process, and subjects will be asked to sign an informed assent form or
consent form (as appropriate) stating that they understand the requirements for avoidance of 
pregnancy during the course of the study. 
During the course of the study, regular serum human chorionic gonadotropin (hCG) pregnancy 
tests will be performed for all female subjects (Appendix A) . In addition to a negative serum hCG 
pregnancy test at Screening, subjects also must have a negative serum hCG pregnancy test prior to
receiving of study medication. 
9.1.11 Pregnancy
If any subject is found to be pregnant during the study, she should be withdrawn, and any 
sponsor-supplied drug should be immediately discontinued. In addition, any pregnancies in the 
partner of a male subject during the study or for 30 days  after the last dose, should also be recorded 
following authorization from the subjectâ€™s partner.CCI
Property of Takeda: For Non-Commercial Use Only and nce Proce Pr
er-age seage 
o be sexbe se
d. It is nd. It is
ve advicve adv
ice fromce fro
ussiossion wn
frfromom thtm
egalgalgugll
sent procnt pro
opriate)opriat
he courhe cou
urse of thse of 
performperfor
y test aty test a
ing of sing of 
.1.11.11
If anIf ase
sd Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 51of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
If the pregnancy occurs during administration o f active study medication, eg, after Day 1 or within 
30 days o f the last dose of active study medicat ion, the pregnancy should be reported immediately, 
using a pregnancy  notificat ion form, to the contact listed in Section 1.0.
Shou ld the pregnancy occur during or after administration of blinded drug, the Investigator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by the Investigator. 
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the Investigator should notify the primary  care physician that the subject/female 
partner of the subject was participat ing in a clinical study  at the time she became pregnant and 
provi de details o f treatm ent the subject received (blinded or unblinded, as applicable).
All pregnancies in subjects on active study drug including co mparator will be fo llowed up to final 
outcom e, using the pregnancy  form. Pregnancies will remain blinded to the study  team . The 
outcom e, including any  premature terminat ion, must be reported to the sponsor. An evaluat ion 
after the bi rth of  the child will also be conducted.
9.1.12 Pharmacogenomi c Sample Collection 
As of the date of this amendment, a suffic ient number of samples have been collected and no more 
are needed; therefore, pharmacogeno mic samples no longer need be taken.
Under previous versio ns of this protocol, s ubjects hadthe opti on to sign the pharmacogenomic 
sample collect ion informed consent form ( ICF) . For those who provide d consent to participate in 
the pharmacogeno mic sub -study , a 1mL who le blood sample for DNA isolation, a 2.5 mL blood 
sample for RNA iso lation, as well as a sa liva sample were to be collected before dosing on Day 1. 
An addit ional 2.5 mL blood sample was to be collected at the Week 12 Visit. If the baseline RN A 
blood sam ple collect ion wasmissed, the Visit 12 blood draw should not have been done. 
DNA form s the basis for the genes that make the body produce proteins such as enzymes, drug 
transporters or drug targets, and may be evaluated for the genet ic contribut ion how the drug is 
broken down, or how the drug affects the body . RNA has mult iple vital roles in the coding, 
decoding, regulat ion, expressio n of genes, and sensing and co mmu nicat ing responses to cellular 
signals. Both DNA and RNA samples may  be evaluated for the genetic and transcriptional 
contribution on how the drug is broken down, or how the drug affe cts the body . Thi s is called a 
â€œPharmacogeno mics research study .â€ Specific purposes of this study  include:
ï‚·Ident
ifying genet ic reasons why certain people respond differently to aloglipt in.
ï‚·Finding out more informat ion about how aloglipt in works.
ï‚·Generat inginformat ion needed for research, development, and regulatory  approval  of tests to 
predi ct response to aloglipt in.
ï‚·Ident ifying variations in genes related to the bio logical target of aloglipt in.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 52 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
This information may be used, for example, to develop a better understanding of the safety and 
efficacy of alogliptin and other study medications, and for improving the efficiency, design, and 
study methods of future research studies.
Samples taken will be stored for no longer than 15 years after completion of the SYR-322_309 
study. No samples will be stored for longer than permitted by the applicable law and samples will 
be destroyed upon notification from Takeda. â€œStored samplesâ€ are defined as samples that are 
key-coded (the samples are stripped of all personal identifying information but a key links the 
samples to the clinical data collected from the sample donor) and are used in the analysis of 
investigational drug or related drugs.
9.1.13 ECG Procedure 
A standard 12-lead ECG will be recorded. The Investigator (or a qualified observer at the 
investigational site) will interpret the ECG us ing 1 of the following cate gories: with in normal 
limits, abnormal but not clinically significant, or a bnormal and clinically significant. A copy of the 
ECG tracing should be kept with the subjectâ€™s notes.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use309 09 
mples wilples w
that arehat ar
eyyllyinks ink
analysianalys
alified oified
ng categg cate
clinicalclinica
perty of Takeda: For Non-Commercial Use Only and S
Alogliptin
Study No. SYR-322_309 Page 53 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
9.1.15 Documentatio n of Screen Failure or Pre-Randomization Stabilization Failures 
Investigators must account for all subjects from whom informed consent/assent has been obtained.If the subject is found to be not eligible during the Screening and Pre-Randomization Stabilization 
Period, the Investigator should complete the eCRF. The IVRS/IWRS should be contacted as a 
notification of screen failure or Pre-Randomization Stabilization failure.
The primary reason for Screen failure/Pre-Rando mization S tabilization failure is rec orded in the 
eCRF using the following categories:
!PTE/AE.
!Did not meet inclusion criteria or did meet exclusion criteria.
!Significant protocol deviation.
!Lost-to-follow-up.
!Voluntary withdrawal <specify reason>.
!Study termination.
!Other <specify reason>.
Subject numbers assigned to subjects who fail Screening/Pre-Rando mization Stabilization s hould 
not be reused.
9.1.16 Documentation of Randomization
Only subjects who meet all of the inclusion criteria  and none of the exclusion criteria are eligible 
for randomization into the treatment phase.CCI
Property of Takeda: For Non-Commercial Use Only and Subjandomando
om inform info
he Screhe Scre
eCRF. eCRF
omizatmizat io
e/Pre/Pre--Ra
es:s:
ncricrinteriteriii
cololdeviadevll
w-up.-up
ywiwiyththiiidr
yytermintermy
Otherther<s<
Subject ubjec
not bnot se
ubject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 54of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
If the subject is found to be not eligible for randomizat ion, the Invest igator should record the 
primary  reason for failure on the app licable eCRF.
9.1.17 Blood Glucose Education and Management
Subjects will meet with a diabetes educator or appropriately trained site personnel at Screening, at 
the Pre -Randomization Stabilizat ion Visits, and at specified Visit s through Week 26, who will 
instruct them on how and when to test their blood glucose levels using their gluco meter, how to 
recogni ze the signs and symptoms of hypoglycemia, and how to use supplemental treatment with 
oral glucose, if necessary. Invest igators should individualize reco mmendat ions for capillary blood 
glucose m easurements based on the subjectsâ€™ level and stabilit y of glycemic control, init iation of 
or change in therapy , intercurrent illness, and risk of hypoglycemia associated with the ty pe and 
intensity of therapy . Timing of gl ucose m easurements should be based on local guidance on the 
management of T2DM in y ouths. For recommendations, see Appendix H.
The gluco meter will be returned by the subject and reviewed by site personnel at every subsequent 
visit.
9.1.17.1 Education on Hypoglycemia
The di abetes educator will instruct subjects on the signs and symptoms of hypoglycemia and on 
the use of supplemental treatment with oral glucose, i f its use i s necessary  during the study .
Any time a subject experiences signs and symptoms of hypoglycemia, they will be instructed to 
measure their blood glucose level wit h the gluco meter and record the value, alo ng with their signs 
and symptoms in the su bject diary. Hypoglycemic events must be recorded in the diary any time a 
subject experiences either of the fo llowing:
ï‚·Signs and symptoms of hypoglycemia (regardless of blood glucose value by finger stick); and
ï‚·Blood gl ucose value by  finger sti ck â‰¤70 mg/dL (3.9 mmo l/L) (regardless of symptoms).
For these hypoglycemic events, subjects must record the fo llowing informat ion in the diary:
ï‚·Date and time o f hypoglycemic event;
ï‚·Symptom s;
ï‚·Blood gl ucose value by  finger sti ck and time of finger sti ck.
Subjects who ex perience symptom s of hypoglycemia, such as hunger, irritation, sweat ing, etc., 
will be instructed to ingest fast -absorbing carbohydrates such as orange juice. If symptoms persist, 
or if the severit y worsens, subjects will be instructed to immediately  seek emergency medical 
attenti on.
9.1.17.2 Definitions of Hypoglycemia 
Subjects will be instructed to test their blood glucose, using their gluco meter, on a daily basis and 
at any  time they  experi ence si gns and symptoms of hy poglycemia, to confirm that it is a 
hypoglycemic episode, as defined below. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 55of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
The fo llowing definit ionsfor severit y apply:
Mild to Moderate Hypoglycemia Criteria:
Blood gl ucose <60 mg/dL (3.33 mmo l/L) in the presence of symptoms, or
Blood gl ucose <50 mg/dL (2.78 mmo l/L) with or without symptoms.
Severe Hypoglycemia Criterion:
Any episode requiring the ass istance of another person to actively administer carbohy drate, 
glucagon, or other resuscitative act ions, associ ated wi th a docum ented bl ood gl ucose 
<60mg/dL (3.33 mmo l/L) (unless the clinical situation makes obtaining a blood glucose 
difficult [eg, it inv olves co ma or seizure]).
If a subject experiences a severe hypoglycemic event, the subject and/or his/her legal 
representative (ie, parent or legal guardian) should be instructed to notify the study  site.
Inform ation regarding any episodes of hypoglycemia shoul d be docum ented in the eCRF.
Subjects will be discont inued fro m study  medication if they  experience severe and/or frequent 
hypoglycemia episodes, defined as â‰¥1 major or severe episode or recurrent non -majo r episodes in 
the event where the possibilit y of down -titration of  contribut ing concomitant medicat ion(s) (other 
than the double -blind study  medicat ion) and/or other con tribut ing factors has been evaluated and 
corrected.
Non-majo r recurrent hy poglycemia is defined as any  recurrent hy poglycemia episode s, as 
determined by the Investigator, not meet ing the definit ion of severe hypoglycemia. It is the 
Invest igatorâ€™s clinical assessment whether the subjects who experience hypoglycemia episodes 
shoul d be discont inued fro m study  medicat ion. 
9.1.17.3 Criteria for Hype rglycemia Rescue 
Subjects will be required to maintain their background antidiabetic therapy , (if applicable) at the 
same dose, throughout the first 26 weeks of the Double -Blind Treatm ent Peri od. 
Subjects m ay be rescued ei ther on the basis of their finge r stick measurements or their HbA1c 
measurements as detailed below.
Subjects will be recommended to test thei r blood glucose l evels via glucom eter m easurements at 
the time po ints recommended in Appendix H. If the subjectâ€™s glucose level (based on 
measurements at any  of the specified time points, eit her fast ing or non -fasting) is determined to 
have remained at >300 m g/dL ( >16.6 mmo l/L) for a period of more than 2 consecut ive days, the 
subject should be instructed to contact the site as soon as possible. The subject should also be 
instructed to contact the site immediately if there are symptoms suggest ive o f decom pensat ion 
such as vomiting, dehydrat ion, lethargy , etc. Upon contact by  the subject/subjectâ€™s parent or 
guardi an, the invest igator (or appropriately -trained study  coordinator) should assess for signs of 
illness and, if appropriate and warranted, schedule a visit to th e site for further assessment of the 
hyperglycemia as well as possible metabo lic decompensation, including measurement of ketones.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 56of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Any subject who meets any  of the fo llowing cri teria, will  be rescued wi th antihyperglycemic 
agents:
ï‚·Subjects with HbA1c value s <7.0% at the Baseline Visit will be rescued if their HbA1c 
remains at >8.0% confirmed by a second sample drawn at the next scheduled visit and 
analyzed by the central laboratory . 
ï‚·Subjects with HbA1c values >7.0% at the Baseline Visit will be rescued if their HbA1c values 
increase by >1.0% as determined by the central laboratory AND confirmed by a second sample 
drawn at the next scheduled visit and analyzed by the central laboratory .
Upon determining that a subject meets the predefined hyperglycemic crit eria, rescue therapy  can 
be added and modified as needed to achieve and maintain adequate glycemic control. Subjects 
who meet the criteria for rescue will cont inue double -blind study  medicat ion, and will cont inue 
participat ion in the study in order to be e valuated for safet y up to 52 weeks.
Please Note: Subjects who require hyperglycemic rescue medications for reasons other than 
efficacy  (ie,metabolic deco mpensat ion or change in clinical status [eg, DKA]) should be rescued 
at the Invest igatorâ€™s discret ion at any  time point during the study . If glucose control  worsens 
unacceptably  in the judgment of the invest igator and requires further intensive invest igation and/or 
management, the subject may be scheduled for an early terminat ion visit and wit hdrawn fro m the 
study . The ci rcumstances surrounding the decompensat ion, along wi th the use and t iming o f all 
related medicat ions will be documented in the eCRF.
Insulin (or increased doses of insulin) may be administered to treat acute metabo lic 
decom pensat ion, which is most commo nly due to an intercurrent illness or non -compliance to 
medical treatment. However, if the supplemental use of insulin extends beyo nd 2 weeks, the 
subject will be considered to have met the hy perglycemic rescue criteria. 
9.1.18 Biomarkers of Bone Tu rnover
In order to evaluate the effects of aloglipt in on bone turnover, biochemical bio markers will be 
measured during the study . 
Serum  concentrati ons of  bone -specific alkaline phosphatase, which is associated with changes in 
bone form ation, will be measu red. 
Serum  concentrati ons of  CTX, whi ch is associ ated wi th changes in bone resorption, will be 
measured.
Blood sam ples for the determinat ion of biochemical bio markers of bone turnover will be collected 
at the Baseline, Week 26, and the End -of-Treatm ent Vi sits. The samples will be collected at the 
same time the safet y laboratory  specimens (i e, chemistry  and hematol ogy) are drawn. 
9.2 Monitoring Subject Treatment Compliance
Subjects will be required to bring study medicat ion containers/unused medicat ions to the next si te 
visit. If a subject is persistent ly nonco mpliant with the study  medicat ion (<70% or >125%) of the 
allocated medicat ion for 2 consecut ive visits after rando mizat ion), it may be appropri ate to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 57of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
withdraw the subject from the study  after consul tationwith the Medical Monitor. All subjects 
shoul d be reinstructed about the dosing requirement during study  contacts. The authorized study  
personnel conduct ing the re -education must document the process in the subject source records.
9.3 Schedule of Observations and Procedures
The schedule for all study -related procedures for all evaluat ions is shown in Appendix A. 
Assessments should be co mpleted at the designated visit/time p oint(s).
For si tes not abl e to conduct onsite visits due to unavoidable circumstances (eg, a wi despread 
disease outbreak such as the COVID -19 pandemic or natural disaster) , acceptable alternat ives to 
assess subject safet y and overall clinical status may  include, but are not limit ed to, vi sits as per 
protocol  schedule conducted by delegated site staff speaking direct ly with the subject by telephone 
or other medium (eg, a computer -based video communicat ion), or sites may send site staff to 
subjects to conduct study assessments, contingent upon local regulat ions.
The End -of-Treatm ent Visit should be performed in person. Alternat ive methods of data collect ion 
may be considered for this visit when it is not possible for the subject to come to the study  site. 
Unde r such ci rcumstances, a preferred alternat ive woul d be f or site staff to go to the subjectâ€™s 
residence and conduct the protocol -specified procedures in that location. Assessments collected at 
subjectsâ€™ residence should comply wit h applicable local regulati ons. 
During contact with the subject by  an al ternat ive method, the study  site physician or other 
qualified site staff should also, at minimum, conduct the fo llowing assessments within 
specified -visit window timeframes : AE assessments, docum entati on of  concomitant m edicat ion, 
review of diaries and gluco meter readings, drug accountabilit y
,and assessment of clinical 
symptoms. Other study  assessments m ay be collected rem otely as i s feasible and may  involve 
audio or vi deo recording. Assessments that cannot be completed during the protocol -specified 
window will be considered missing data, and such departures will be recorded in the study records. 
Alternat ively, sites may seek approval to extend the visit window up to 3times the 
protocol -specified window ( Appendix A) in order to conduct an onsite visit.
The interval between successive visit s when clinical laboratory  tests and vi tal sign measurements 
are perform ed m ay not be l onger than 8 weeks.
9.3.1 Screeni ng
Subjects will be screened within 14 days pri or to randomizat ion/Day 1 or the Pre -Rando mizat ion 
Stabilizat ion Peri od (if applicable) as indicated in Appendix A. Subj ects will be screened in 
accordance with predefined inclusio n and exclusio n criteria as described in Sect ions 7.1and 7.2.
 
See Section 9.1.15 for procedures for document ing Screening failures. Subjects must also meet all
criteria specified in Section
 7.3to proceed direct ly to the Day  1 visit (ie, not enter the 
Pre-Rando mizat ion Stabilizat ion Peri od).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 58of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
9.3.2 Pre-Randomization Stabilization Period
Subjects will part icipate in the Pre -Randomization Stabilizat ion Peri od until entry  criteria and the 
objectives of the Pre -Rando mizat ion Stabilizat ion Peri od have been met (Please refer to 
Secti on6.2for addit ional informat ion). Subjects will return to the clinic for assessments at regular 
intervals during the Pre -Randomization Stabilization Period at the invest igatorâ€™s discretion, but at 
least every  3 months, as shown in
 Appendix A.
Subjects will be informed how to recognize signs and symptoms of hypoglycemia and will 
measure their fasted blood glucose at least once a day . 
See Secti on 9.1.15 for procedures for document ing Pre-Randomizat ion Stabilizati on failures.
9.3.3 Week -1
Subjects who participate in the Pre -Randomizat ion Stabilizat ion Period, regardless of the duration, 
will return to the clinic at Week -1 to confirm qualificat ionfor all inclusio n and exclusion criteria 
specified in Section
 7.3. 
9.3.4 Randomization
If the subject has sat isfied all o f the inclusio n criteria (inclu ding the addi tional rando mization 
criteria that must be m et following Screening and/or complet ion of the Pre -Rando mizat ion 
Stabilizat ion Peri od) and none of the exclusio n criteria for randomizat ion, the subject should be 
rando mized using the IVRS/IWRS on D ay 1, as described in Sect ion
 8.2. Subj ects will be 
instructed on when to take the first dose of invest igational drug as described in Sect ion 6.1. The 
procedure for document ing Screening and/or Pre -Rando mizat ion Stabilizat ion failures is provided 
in Section 9.1.15 .
9.3.5 Double -Blind Treatment Period
In addit ion to receiving double -blind study  medicati on, subjects will be required to maintain their 
background antidiabetic therapy , at the sam e dose , throughout the first 26 weeks of the 
Doubl e
-Blind Treatm ent Peri od.
Subjects who meet protocol -defined hyperglycemia rescue criteria (ie, for efficacy reasons) should 
be rescued wit h ant idiabet ic medicat ions, at the Investigatorâ€™s discret ion. (Refer to 
Section9.1.17.3 ). Subjects who are administered hyperglycemic rescue therapy prior to Week 26 
will cont inue double -blind study  medicat ion, and will cont inue part icipation in the study in order 
to be evaluated for safet y up to 52 weeks. 
Subjects who terminate double -blind study  drug prem aturely  will continue to be followed at their 
regul arly scheduled study  visit s time points for the 52
-week duration of the study. S ubjects will 
complete an End -of-Treatm ent Visit and Fo llow-Up Visit, 2 weeks after the last dose of study drug, 
and a Proj ected Week 52 Visit. 
Some subjects m ay require temporary  suspensi on of study  medicat ion and the use of insulin (or 
increased doses of insulin). If the acute event resolves and insulin is wit hdrawn or returned to the 
maintenance level wit hin 2 weeks, the subject can continue in the study. If the supplemental use o f 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 59of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
insulin extends beyo nd 2 weeks, the subject will be considered to have me t the hyperglycemic 
rescue criteria. 
A schedule o f assessments is listed in Appendix A.
9.3.6 Unscheduled Visit (As Applicable)
Subjects may return to the study center for unscheduled visits as needed. Unscheduled study visits 
can be performed when the subject has a study  related i ssue in between regular study  visits or as 
needed to ensure subject safet y. 
The fo llowing procedures should be performed during this visit:
ï‚·Concomitant medicat ions review.
ï‚·Other protocol procedures, including collect ion of blood and urine samples, as deemed 
appropriate by  the Invest igator. 
ï‚·AE assessment.
ï‚·Blood gl ucose and HbA1c concentration laboratory samples will be collected as directed in 
section 9.1.17 .
9.3.7 End-
of-Treatment Visit
The End -of-Treatm ent Vi sit will be performed at Week 52 or after the last dose of study  drug.
For all subjects receiving study  medicati on, the investi gator m ust com plete the End -of-Treatment 
eCRF page. A schedule of assessments performed at the end of treatment visit is listed in 
Appendix A
.
9.3.8 Follow -up Visit
A follow-up visit will be conducted via telephone with the subject 2 weeks after the 
End-of-Treatm ent Visi t. A schedule of assessments performed at the follow-up visi t is listed in 
Appendix A.
9.3.9 Projected Week 52 Visit
Subjects who prematurely discont inue study  drug and continue telephone (or other 
communicat ion) co ntact will follow the protocol -specified visit schedule for the remainder of the 
52-week treatment period. The Projected Week 52 Visit should be conducted at the clinic, if at all 
possible. 
9.3.10 Post Study Care
The study  medicat ion will not be provided by the sponsor upon complet ion of the subjectâ€™s 
participat ion in the study. The subject should be returned to the care of a physician and standard 
therapi es shoul d be init iated, as required. Subjects will be offered clinical fo llow
-up examinat ions 
as considered a ppropri ate per the treating physician.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 60of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
9.4 Biological Sample Retention and Destruction
As of the date of this amendment, a suffic ient number of samples have been collected and no more 
are needed; therefore, pharmacogeno mic samples no longer need be taken.
Unde r previous versio ns of this protocol, specimens for genome/gene analysis were to be collected 
as described in Sect ion9.1.12 . After extraction and purificat ion, the genetic material was to be 
preserved and retained for up to, but not longer than, 15 years or as required by applicable law. The 
sponsor has put into pl ace a system to protect the subjectsâ€™ personal informat ion to ensure optima l 
confident iality and defined standard processes for sample and data collect ion, storage, analysis, 
and destruction.
The samples were to be sent to a central laboratory that process es the blood sample and serves as a 
secure storage facilit y. The samples were to be stored init ially at PPD Laboratory  and then sent to 
Covance Laboratories for long -term storage. The sponsor and researchers working wit h the 
sponsor will have access to thesamples co llected and any test resul ts. All samples co llected during 
the study  will be stored securely  with limited access and the sponsor will require any one who 
works wi th the sam ples to agree to hol d the research informat ion and any results in confiden ce.
The sample was to be labeled wit h a unique sample ident ifier similar to labeling in the main study 
but using a code that is different fro m the code attached to the healt h informat ion and other clinica l 
test results collected in the study . The sample an d data are linked to personal healt h informat ion 
with code numbers. This link means that the subject may  be ident ified but only indirect ly. The 
code numbers will be kept secure by  or on behalf of the sponsor.
Subjects who consented and provided a pharmacogeno mic sample for DNA and/or RNA analysis 
couldwithdraw thei r consent and request di sposal  of a stored sam ple at any  time. The s ponsor 
shoul d be notified of consent withdrawal.
10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS
10.1 Definitions
10.1.1 PTEs
A PTE i s defined as an y untoward m edical  occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study  but pri or to administration of any study  
medicat ion; it does not necessarily have to have a causal relat ionship with study  parti cipation.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject 
administered a drug; it does not necessarily have to have a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unintended sig n (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug whether or 
not it is considered related to the drug.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 61of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:
ï‚·Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions underlying disease should not be considered PTEs or AEs.)
ï‚·Necessitate therapeutic intervent ion.
ï‚·Requi re an invasive diagnosti c procedure.
ï‚·Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
ï‚·Be considered unfavorable by the Investigator for any reason.
ï‚·PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:
ï‚·Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or as an AE(s).
Laboratory  values and ECG findings:
ï‚·Changes in laboratory values or ECG paramete rs are only considered to be PTEs or AEs if the y 
are judged to be clinically significant (i e, if so me action or intervent ion is required or if the 
Invest igator judges the change to be beyo nd the range of normal physio logic fluctuati on). A 
laboratory  re-test and/or continued monitoring o f an abnormal value are not considered an 
intervent ion. In addit ion, repeated or addit ional noninvasive testing for verificat ion, evaluatio n 
or monitoring of an abnormalit y is not considered an intervent ion.
ï‚·If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as a PTE or as an AE.
Pre-exist ing condit ions:
ï‚·Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, ECG, X -rays etc.) should NOT be recorded as PTEs unless 
related to study  procedures. However, if the subject experiences a worsening or co mplication 
of such a concurrent condit ion, the worsening or complicat ion shoul d be recorded 
appropriately  as a PTE (worsening or complicat ion occurs before start of study medicat ion) or 
an AE (worsening or complicat ion occurs after start of study medicat ion). Investigators should 
ensure that the event term recorded captures the change in the condit ion (eg, â€œworsening 
ofâ€¦â€).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 62of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
ï‚·If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy) any occurrence of an 
episode should only be captured as a PTE /AE if the episodes become more frequent, serious, or 
severe in nature, that is, Investigators should ensure that the AE term recorded captures the 
change in the condit ion from Baseline (eg â€œworsening ofâ€¦â€).
ï‚·If a subject has a degenerat ive concurrent condi tion (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion shoul d only  be captured as a PTE/AE if occurring to a greater 
extent to that which would be expected. Invest igators should ensure that the AE term recorded 
captures the change in t he condit ion (eg, â€œworsening ofâ€¦â€).
Worsening of PTEs or AEs:
ï‚·If the subject experiences a worsening or complicatio n of a PTE after starting administration of 
the study  medicat ion, the worsening or complicat ion should be recorded appropriately as an 
AE. In vestigators should ensure that the AE term recorded captures the change in the condit ion 
(eg, â€œworsening ofâ€¦â€).
ï‚·If the subject experiences a worsening or complication of an AE after any  change in study  
medicat ion, the worsening or complicat ion should be re corded as a new AE. Investigators 
shoul d ensure that the AE term recorded captures the change in the condit ion (eg, â€œworsening 
ofâ€¦â€).
Changes in severit y of AEs /Seri ous PTEs:
ï‚·If the subject experiences changes in severit y of an AE/seri ous PTE, the event s hould be 
captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
ï‚·Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
perform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
worsening of the condit ion should be captured appropriately as a PTE or an AE. Complicat ions 
resul ting fro m any planned surgery  shoul d be reported as A Es.
Elect ive surgeries or procedures:
ï‚·Elect ive procedures performed where there is no change in the subjectâ€™s medical condit ion 
shoul d not be recorded as PTEs or AEs, but should be documented in the subjectâ€™s source 
docum ents. Com plicat ions result ing from an elective surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
ï‚·Insufficient clinical response, efficacy, or pharmacologic act ion should NOT be recorded as an 
AE. The Investigator must make the distinct ion between exacerba tion of  pre-exist ing illness 
and lack of therapeutic efficacy.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 63of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Overdose:
ï‚·Cases of overdose with any  medicati on wi thout m anifested si de effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested si de effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
ï‚·The term â€œlife threateningâ€ refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4.Results in pe rsistent or si gnificant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
ï‚·May require intervent ion to prevent items 1 through 5 above.
ï‚·May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
ï‚·Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 64of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Table 10.a Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndromeHepatic necrosis
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary fibrosis 
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens -Johnson 
syndromeConfirmed or suspected transmission of infectious agent by 
a medicinal product
Neuroleptic malignant syndrome/malignant 
hyperthermiaCOVID -19-related -disease
Spontaneous abortio n/stillbirth and fetal death COVID -19 pneumonia
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and fo llowed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5 Special Interest AEs 
A special interest AE (serious or non -serious) is one of scientific and medical concern specific to 
the com pound or program , for which ongoing monitoring and rapid communicat ion by the 
Invest igator to Takeda may be appropriate. Such events may require further invest igation in order 
to characterize and unders tand them and would be described in protocols and instructions provided 
for Invest igators as to how and when they should be reported to Takeda.
The site is required to actively  obtain addi tional clinical informat ion on the fo llowing adverse 
event of specia l interests (AESIs): Serious hepat ic abnorm alities, pancreat itis, infect ions 
(including urinary  tract infect ions), and severe hypersensit ivity react ions including angioedema, 
anaphylaxis, and Stevens -Johnson Syndrome. 
Targeted follow -up forms have been de veloped to further guide the collect ion of data of AESIs and 
the form s need to be submitted to the sponsor as part of the AEs source documents.
10.1.6 Severity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by the subject.
Moderate: The event causes the subject discomfort and interrupts the subjectâ€™s usual activities.
Severe: The event causes considerable interference with the subjectâ€™s usual activities.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 65of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
10.1.7 Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs,and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant drugs,and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The relationship should be assessed as related if the Invest igator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relations hip should be assessed 
as not related. 
10.1.9 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by  the subject 
and/or Invest igator.
10.1.10 Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.1.11 Frequency 
Episodi c AEs/PTE (eg, vomit ing) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.12 Action Concerning Study Medication 
ï‚·Drug w ithdrawn â€“a study  medicat ion is stopped due to the particular AE.
ï‚·Dose not changed â€“the particular AE did not require stopping a study  medicat ion.
ï‚·Unknown â€“only to be used if it has not been possible to determine what action has been taken.
ï‚·Not Applicable â€“a study  medicati on was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the subject died, dosing with study  medicat ion was already 
stopped before the onset of the AE.
ï‚·Dose interrupted â€“the dose was interrupted due to the particular AE.
Some subjects m ay require temporary  suspensi on of study  medicat ion and the use of insulin. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 66of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
10.1.13 Outcome
ï‚·Recovered/reso lved â€“ Subject returned to first assessment status with respect to the AE/PTE.
ï‚·Recovering/resolving â€“the intensit y is lowered by  one or m ore stages; the diagnosis or 
signs/symptom s has almost di sappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AE/PTE with the c ondition rem aining â€œrecovering/reso lving.â€
ï‚·Not recovered/not resolved â€“there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/ symptom s or laboratory  value on the last day  of the observed 
study  period has got worse t han when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE/PTE state remaining â€œNot 
recovered/not resolvedâ€.
ï‚·Reso lved with sequelae â€“the subject recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
ï‚·Fatal  
â€“the AEs/PTEs which are considered as the cause of death. 
ï‚·Unknown â€“the course of the AE/PTE cannot be followed up due to hospital change or 
residence change at the end of the subjectâ€™s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTE and AE Collection Period
Collect ion of PTEs will co mmence from the time the subject signs the informed consent to 
participate in the study  and cont inue until the subject is first administered study medicat ion 
(Day 1) or until Screen/Stabilization failure. For subjects who discont inue prior to study 
medicat ion administration, PTEs are collected until the subject discontinues study participat ion.
Collect ion of AEs will co mmence fro m the time that the subject is first administered study  
medicat ion (Day  1). Routine collect ion of AEs will continue unt il the Follow -up Visi t.
10.2.1.2 PTE and AE Reporting
At each study  visit, the Invest igator wi ll assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as â€œHow have you been feeling since your last visit ?â€ may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing a 
serious PTE m ust be monitored until the symptoms subside and any clinically relevant changes in 
laboratory  values have returned to Baseline or there is a sat isfactory  explanati on for the change. 
Non-serious PTEs, rel ated or unrel ated to the study  procedure, need not be fol lowed-up for the 
purposes of the protocol.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 67of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the Invest igator concludes that the event is related to the drug treatment. The 
following informat ion will be documented for each event:
1.Event term .
2.Start and stop date.
3.Severit y.
4.Invest igatorâ€™s opinio n of the causal relat ionship between the event and administration of study 
medicat ion(s) (rel ated or not rel ated) (not completed for PTEs).
5.Invest igatorâ€™s opinio n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
6.Action concerning study  medicat ion (not applicable for PTEs).
7.Outcom e of event.
8.Seriousness.
10.2.1.3 Special Interest AE Reporting 
Ifa special interest AE occurs during the treatment period or the fo llow-up peri od,and is 
considered to be clinically significant based on the criteria below, it should be report ed to the 
sponsor (described in the separate contact informatio n list) immedia tely or wi thin 1 business day 
of first onset or subjectâ€™s notificat ion of the event .A special interest AE name f orm or an SAE 
form shoul d be com pleted, signed, and/or sealed by  the PI, and reported to appropriate personnel 
in the separate contact informat ion list within 10 business days.
ï‚·Laboratory  value threshold if applicable.
ï‚·Prem ature termination for the special interest AE, if applicable.
ï‚·Any other specific criteria.
The special interest AEs have to be recorded as AEs in the eCRF. An evaluat ion form along wit h 
all other required documentation must be submitted to the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 68of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be complete d, in English and signed by the Invest igator immediately or 
within 24 hours of first onset or notificat ion of the event. The informat ion should be completed as 
fully as possible but contain, at a minimum:
ï‚·A short descript ion of the event and the reason why the event i s categori zed as serious.
ï‚·Subject identificat ion number.
ï‚·Invest igatorâ€™s name.
ï‚·Nam e of the study  medicat ion(s).
ï‚·Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 1.1.
Any SAE spontaneously reported to the Invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  participat ion.
Reporting of Serious PTEs will fo llow the procedure described for SAEs.
10.2.3 Reporting of Abnormal Liver Function Tests 
If a subject is noted to have elevated ALT or AST levels >3 Ã—ULN please see Sect ion 7.8for 
instructi ons for reporting and managing the subject.
10.3 Follow -up of SAEs
If informat ion not available at the time of the first report becomes available at a later date, the 
Invest igator sho uld com plete a follow -up SAE form or provide other written documentation and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be se nt to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, including the EMA, 
Invest igators and IRBs, as applicable, i n accordance with nat ional regulations in the countries 
where the study is conducted. Relat ive to the first awareness o f the event by/or further provisio n to 
the sponsor or sponsorâ€™s designee, SUSARs will be submitted to the regulatory  authori ties as 
exped ited report wi thin 7 days for fatal and life -threatening events and 15 days for other serious 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 69of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
events, unless otherwise required by nat ional regulations. The sponsor will also prepare an 
expedited report for other safet y issues where these might materially alter the current benefit -risk 
assessment of an investigational medicinal product or that would be sufficient to consider changes 
in the invest igational medicinal products administration or in the overall conduct of the study . The 
investigat ional site also will forward a copy  of all expedited reports to his or her IRB or IEC in 
accordance with nat ional regulat ions.
11.0 STUDY- SPECIFIC COMMITTEES
11.1 Independent Data Monitoring Committee
An independent DMC will be established to periodically review study safet y data. Details o f the 
DMC m embership and responsibilit ies will be detailed in a DMC Charter. The outcome of data 
reviews by the DMC will be co mmunicated to the local IRBs/ECs, where appropriate, as per local 
regul ations.
12.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history, and concurrent condit ions will be coded using the MedDRA (Medica l 
Dictionary for Regulatory  Activities). Drugs will be coded using the WHODR UG (Worl d Heal th 
Organizat ion Drug Di ctionary).
12.1 CRFs (Electronic)
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangeme nts to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed dire ctly onto eCRFs.
After complet ion of the entry  process, com puter l ogic checks will be run to ident ify items such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded in an audit trail that captures the old information, the new informat ion, ID 
of the person making the correction, the date the correction was made, and the reason for change.
The PI m ust revi ew the eCRFs for completenes s and accuracy and must sign and date the 
appropriate eCRFs as indicated. Furthermore, the Investigator must retain full responsibilit y for 
the accuracy  and authenticit y of all data entered onto the eCRF.
The eCRFs will be reviewed for completeness and acc eptabilit y at the study  site during peri odic 
visits by study  monitors. The sponsor or i ts desi gnee will  be permitted to review the subjectâ€™s 
medical and hospital records pertinent to the study  to ensure accuracy  of the eCRFs. The 
completed eCRFs are the so le property of the sponsor and should not be made available in any 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 70of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regul atory  authori ties, wi thout wri tten permissio n of the sponsor.
12.2 Record Retention
The Investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific docum ents, the i dentificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal healt h inform ation (if separate from the ICFs), electronic copy  of eCRFs, including the 
audit trail, and detailed records of drug disposit ion to enable evaluat ions or audits from regulatory 
authori ties, the sponsor or its designees. Any source documentation printed on degradable thermal 
sensit ive paper should be photocopied by the site and filed with the original in the subjectâ€™s chart 
to ensure long term legibilit y. Furthermore, International Conference on Harmonisat ion (ICH) E6 
Secti on 4.9.5 requi res the Invest igator to retain essent ial docum ents specified in ICH E6 
(Secti on8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorities are notified. In addit ion, ICH E6 
Secti on4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the Invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsorâ€™s requirements on record retention. The 
Invest igator should contact and receive written approval fro m the sponsor before disp osing of any 
such documents.
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A SAP will be prepared and finalized prior to unblinding of subjectsâ€™ treatment assignments. This 
docum ent will provi de further details regarding the definit ions of analysis variables and analysis 
methodol ogy to address all study  objectives. The SAP will address the characterizat ion of study  
subjects potentially impacted by  COVID -19 and supportive analyses to assist in the interpretatio n 
of the overall study  resul ts.
A blinded data review will be conducted prior to unblinding of subjectsâ€™ treatment assignments. 
This review will assess the accuracy and completeness of the study database, subject evaluabilit y, 
and appropriateness o f the planned statist ical methods.
13.1.1 Analysis Sets
The safet y set will include all subjects who took at least 1 dose of study  medicati on. In safet y 
summaries, subjects will be analyzed according to the treatment most often received.
The full analysis set (FAS) will include all rando mized subjects in the sa fety set. F or a parti cular 
variable, the FAS analysis will consist of all subjects who have a baseline assessment and at least 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 71 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
1 postbaseline assessment for the variable. In FAS efficacy summaries, subjects will be analyzed 
as randomized. The per protocol set (PPS) will include all FAS subjects who had no major 
protocol violations. Major protocol violations will be defined prior to database lock.
13.1.2 Analysis of Demographics a nd Other Baseline Characteristics
Subject disposition will be summarized (frequency, percentage) by treatment group for each 
subject sample, incidence of discontinuation, reason for discontinuation, and incidence of rescue. 
The summary of all randomized subjects will include a breakdown by the stratification factors for 
schedule.
Baseline and demographic information will be listed and summarized by treatment group and 
overall. For continuous variables, the summary will consist of descriptive statistics (number of 
subjects, mean, standard deviation, minimum, median, and maximum). For categorical variables, 
the summary will consist of number and percentage of subjects in each category. 
13.1.3 Efficacy Analysis
The primary efficacy variable will be the change from Baseline in HbA1c at Week 26. The primary 
analysis set will be the FAS. Supportive analyses will be conducted with the PPS. A sensitivity 
analysis that excludes subjects affected by COVID-19 will be performed on the primary endpoint. 
The definition of â€œaffected by COVID-19â€ will be provided in the SAP.
The primary analysis will be conducted using a contrast at Week 26 derived from a mixed model 
for repeated measures (MMRM) with change from Baseline in HbA1c as the response variable, 
treatment, visit, and visit-by-treatment inter action as fixed categorical effects, and baseline HbA1c 
and visit-by-baseline HbA1c interaction as continuous covariates. An unstructured 
variance-covariance matrix will be used; parameter estimates will be calculated using restricted 
maximum-likelihood estimation. Degrees of freedom will be estimated using the Kenward-Roger 
approximation. Data collected following discontinuation of double-blind study medication or 
hyperglycemic rescue w ill be censored. 
The secondary efficacy variable will be analyzed using additional contrasts at Weeks 12, 18, 39, 
and 52 derived from the primary analysis model. Continuous exploratory efficacy variables will be 
analyzed using models similar to the primary an alysis model. Categorical variables and time to 
hyperglycemic rescue will be analyzed using logistic regression models and a Cox regression 
model, respectively. An appropriate normalizing transfor mation (eg, natural log) will be applied in 
the event that an exploratory variable is not normally distributed. 
If a subject is diagnosed with MODY during the study, a description of the results will be provided 
separately for each individual subject with MODY, and additional analyses will be performed that 
exclude MODY subjects.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Teroup foroup fo
inincidencide
stratificratific
zed by ted by 
escriptscript i
maximummaximu
bjects inbjects in
from Barom 
yses wiles wi
COVIDCOV
19â€ will19â€ wi
cted usined us
with chwith c
eatmatmente
c interainter
trix willix wi
estimatestim
ta collea coll
rescue wrescue
aryary effic efyy
erived ferived
zed usinzed us
perglyceergly
moodeldel
ththe eeso f  U s e
ITerms of
Alogliptin
Study No. SYR-322_309 Page 72 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
13.1.5 Safety Analysis
Safety parameters will be summarized using descriptive statistics or frequency counts as 
appropriate. Separate summaries using (1) data collected prior to discontinuation of double-blind 
study medication or hyperglycemic rescue (if applicable) and (2) all data will be conducted. 
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3 Determination of Sample Size
The primary efficacy variable will be the change from Baseline in HbA1c at Week 26. The primary 
analysis set will be the FAS. For this variable and set, a total of 75 randomized subjects per 
treatment group will ensure at least 90% power to detect a difference in mean change from 
Baseline in HbA1c at Week 26 between alogliptin 25 mg QD and placebo assuming a treatment 
effect of 0.5%, a SD of 0.9%, and a 2-sided false-rejection rate of 5%. 
14.0 QUALITY CONTROL AND QUALITY ASSURANCE14.1 Study-Site Monitoring Visits
Monitoring visits to the study site will be mad e periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The Investigator and institution guarantee access to source documents by the sponsor or its 
designee contract research organization and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Investigatorâ€™s Binder, 
study medication, subject medical records, informed consent documentation, documentation of 
subject authorization to use personal health information (if separate from the ICFs), and review of 
eCRFs and associated source documents. It is important that the Investigator and other study
personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
14.2 Protocol Deviations
The Investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unavoidable circumstances arise (eg, a 
widespread disease outbreak such as the COVI D-19 pandemic or natural disaster) that will require CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Tcounts acounts
tioon of n o
will be ill be 
Baselineaselin
et, a tota a to
o dedetecttec
iptptin 25 in 25
falsealse-r
D QUALQUA
g VisitsVisit
dyysisiyte wte iii
e fofollollow
. SourcSour
d institudi n s t i
t researct resea
of the stuf the s
s blindiblind
medicatedica i
ect authect aut
CRFs aRFs
personpers
prpUse
Terms of Us
Alogliptin
Study No. SYR -322_309 Page 73of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
deviat ion from protocol -specified procedures, the Investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. The re will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subjectâ€™s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or its designee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protoco l Deviat ion Form /eCRF shoul d be com pleted by  the si te and electronically 
signed by the sponsor or designee for any  significant deviation from the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qua lity assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medicati on is stored and prepared, and any  other facili ty used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the sponsor should be notified 
immediately . The Invest igator and institution guarantee access for qualit y assurance auditors to all 
study  docum ents as described in Section 14.1.
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declarat ion of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each Invest igator will  conduct the study  
according to applicable local or regional regulatory requirements and align his or her conduct in 
accordance with the â€œResponsibilit ies of the Investigatorâ€ that are listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and Invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable federal/local requirements of each 
participat ing region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC has 
direct parti cipat ion in this study , written notification regarding his or her abstinence fro m voting 
must also be obtained. Those Americas sites unwilling to provide names and tit les of all members 
due to privacy and conflict of interest concerns shoul d instead provi de a Federal  Wide Assurance 
Number or comparable number assigned by the Department of Healt h and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocolâ€™s revie w and approval. This protocol, the Invest igatorâ€™s Brochure, a copy o f 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 74of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
the ICF, and, if applicable, subject recruitment materials and/or advertisements and other 
docum ents requi red by all applicable l aws and regul ations, m ust be submitted to a central or lo cal 
IRB or IEC for approval. The IRBâ€™s or IECâ€™s written approval o f the protocol  and subject 
inform ed consent m ust be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or st udy specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, ICF) reviewed; and state the 
approval  date. The sponsor or designee will notify t he site once the sponsor has confirmed the 
adequacy  of site regul atory  docum entati on and, when applicable, the sponsor has received 
permission fro m competent authorit y to begin the study . Until the site receives notification no 
protocol  activit ies, includi ng screening may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  subjec ts, local safety reporting requirements, reports, and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submissio n of the Investigatorâ€™s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.2 Subject Information, Info rmed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. Th e ICF, subject authorizat ion form (if applicable), and subject 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subjectâ€™s personal and personal healt h informat ion for purposes of conducting 
the study. The ICF and the subject informat ion sheet (if applicable) further explain the nature of 
the study , its obj ectives, and potential risks and benefits, as well as the date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicabl e, the subject authorizat ion form. The ICF, subject authorization form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor prior to use.
The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective subject. It is the 
responsibilit y of the Invest igator to explain the detailed elements of the ICF, subject authorizat ion 
form (if applicabl e), and subject informat ion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possible and in the manner deemed 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 75of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
appropriate by the IRB or IEC. In the event the subject is not capable of rendering adequ ate written 
inform ed consent, then the subjectâ€™s legally  acceptable representative may  provide such consent 
for the subject in accordance with applicable laws and regulations.
The subject, or the subjectâ€™s legally acceptable representative, must be given a mple opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subjectâ€™s legally acceptable representative, determines he or she will part icipate in 
the study , then the ICF and subject authorizat ion form (if applicable) must be signed and dated by 
the subject, or the subjectâ€™s legally acceptable representative, at the time of consent and prior to the 
subject entering into the study . The subject or the subjectâ€™s legally  acceptable representative 
shoul d be instructed to si gn using thei r legal names, not ni cknames, using blue or black ballpo int 
ink. The Invest igator must also sign and date the ICF and subject auth orization (if applicable) at 
the time of consent and prior to subject e ntering into the study; however, the sponsor may allow a 
designee of the Invest igator to sign to the extent permitted by applicable law.
Once signed, the original ICF, subject authorizat ion form (if applicable), and subject informat ion 
sheet (if applicable ) will be stored in the Invest igatorâ€™s site file. The Invest igator must document 
the date the subject signs the informed consent in the subjectâ€™s medical record. Copies of the 
signed ICF, the signed subject authorizat ion form (if applicable), and subject i nform ation sheet (if 
applicable) shall be given to the subject.
All revised ICF must be reviewed and signed by relevant subjects or the relevant subjectâ€™s legally 
acceptable representative in the same manner as the original informed consent. The date the 
revised consent was obtained should be recorded in the subjectâ€™s medical record, and the subject 
shoul d receive a copy  of the revised ICF.
15.3 Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subjectâ€™s right to protection
against invasio n of privacy. Throughout this study , a subjectâ€™s source data will only be linked to 
the sponsorâ€™s clinical study  database or documentation via a unique ID number. As permitted by  
all applicable laws and regulations, limited subject attribut es, such as sex, age, or date of birth, and 
subject init ials may be used to verify the subject and accuracy  of the subjectâ€™s unique ID number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the Inves tigator to permi t its monitor or designeeâ€™s m onitor, representatives from  any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsorâ€™s designated auditors, and the 
approp riate IRBs and IECs to review the subjectâ€™s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subjec tâ€™s study  partici pation, 
and autopsy  reports. Access to a subjectâ€™s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collecte d on the subjectâ€™s eCRF).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 76of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The Invest igator is obliged to provide the sponsor with complete test results and all data derived by 
the Invest igator from the study. Duri ng and after the study , only  the sponsor m ay make study  
inform ation available to other study  Invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study  (including data and informatio n 
generated by  the Invest igator) without the consent of the Invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will preva il.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register 
intervent ional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard. Takeda 
contact informat ion, along with Investigatorâ€™s city, state (for Americas Invest igators), country, and 
recrui ting status will be r egistered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating trial sites closest to their ho mes by 
provi ding the Invest igator name, address, and phone number to the callers request ing trial 
inform ation. Once subj ects receive Investigator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks ad ditional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any Invest igator who objects to Takeda providing this information to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not b e listed on the registry  site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
15.5 Insura nce and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsorâ€™s 
designee will obtain c linical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clinical Study  Site Agreement regarding the sponsorâ€™s policy on subject 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 77of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
compensat ion and treatment for injury. If the Investigator has questions regarding this poli cy, he or 
she should contact the sponsor or sponsorâ€™s designee.
16.0 REFERENCES
1.Albert i G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Ty pe 2 di abetes in the 
young: the evo lving epidemic: the internat ional diabetes federat ion cons ensus workshop. 
Diabetes Care 2004;27(7):1798-811.
2.American Diabetes Association. Standards of medical care for patients with diabetes mellitus. 
Diabetes Care 2003;26 Suppl 1:S33 -50.
3.Barroso I. Genet ics of Type 2 diabetes. Diabet Med 2005;22(5):517 -35.
4.BlÃ¼her S, Kiess W, BÃ¶ttner A, Raile K, Kapellen T, BlÃ¼her M. Ty pe 2 di abetes m ellitus in 
children and ado lescents: the European perspective. In: Kiess W, Marcus C, Wabitsch M, 
editors. Obesit y in Childhood and Ado lescence. Basel, Switzerland: Karger; 2004, p. 170 -80.
5.Drucker DJ. Incretin -based therapies: a clinical need filled by  unique metabolic effects. 
Diabetes Educ 2006;32 Suppl 2:65S -71S.
6.Gungor N, Arslanian S. Pathophy siology of  type 2 diabetes mellitus in children and 
adolescents: treatm ent implicat ions. erratum in: Treat Endocrino l. 2003;2(2):143. Treat 
Endocrino l 2002;1(6):359 -
71.
7.Gungor N, Hannon T, Libman I, Bacha F, Arslanian S. Ty pe 2 di abetes m ellitus in y outh: the 
complete pi cture to date. Pediatr Clin North Am 2005;52(6):1579 -609.
8.Rosenbloo m AL. Increasing incidence of t ype 2 diabetes in children and ado lescents: 
treatm ent considerat ions. Paediatr Drugs 2002;4(4):209 -
21.
9.Vivian EM. Ty pe 2 di abetes in children and adolescents --the next epidemic? Curr Med Res 
Opin 2006;22(2) :297-306.
10.American Diabetes Associat ion. Ty pe 2 di abetes in children and adolescents. Diabetes Care 
2000;23(3):381 -9.
11.Gahagan S, Silverstein J. Prevent ion and treatment of type 2 diabetes mellitus in children, wit h 
special emphasis on American Indian and Alaska Native children. American Academy  of 
Pediatrics Committee on Native American Child Health. Pediatrics 2003;112(4):e328.
12.Gaylor AS, Condren ME. Ty pe 2 diabetes m ellitus in the pediatri c popul ation. 
Pharmacotherapy  2004;24(7):871 -8.
13.Jacobson -Dickman E, Levitsky L. Oral agents in managing diabetes mellitus in children and 
adolescents. Pedi atr Clin North Am  2005;52(6):1689 -703.
14.Von Karla V, Hewett ML. Ty pe 2 di abetes in children and adolescents: screening, diagnosis, 
and management. JA APA 2007;20(3):51-4.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 78of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
15. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. Beta- cell 
funct ion across the spectrum of glucose tolerance in obese youth. Diabetes 
2005;54(6):1735 -43.
16.Dabelea D, May er-Davis EJ, Say dah S, Im peratore G, Linder B, Divers J, et al. Prevalence of 
type 1 and t ype 2 diabetes among children and adolescents fro m 2001 to 2009. JAMA 
2014;311(17):1778 -86.
17.Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, et al. Projections of 
type 1 and t ype 2 diabetes burden in the U.S. populat ion aged <20 y ears through 2050: 
dynamic modeling o f incidence, mortalit y, and popul ation growth. Diabetes Care 
2012;35(12):2515 -20.
18. Fagot- Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 
diabetes am ong North American children and adolescents: an epidemio logic review and a 
public healt h perspect ive. J Pediatr 2000;136(5):664 -72.
19.Miller JL, Silverstein JH. The treatment of type 2 diabetes mellitus in youth : which therapies? 
Treat Endocrino l 2006;5(4):201 -10.
20.Pinhas-Hamiel O, Zei tler P. The gl obal spread of type 2 di abetes mellitus in children and 
adolescents. J Pedi atr 2005;146(5):693 -700.
21.Coburn MC, Hixson DC, Reichner JS. In vitro immune responsiveness o f rats l acking ac tive 
dipeptidylpept idase IV. Cell Immuno l 1994;158(2):269 -80.
22.Copeland KY, Becker D, Cottschalk M, Hale D. Type 2 diabetes in children and ado lescents: 
risk factors, diagnosis, and treatment. Pediatr Diabeties 2005;23(4):181 -5.
23.Drucker DJ. The bio logy of incretin hormones. Cell Metab 2006;3(3):153 -65.
24.Hall CA, Jacques PF. Weighing in on the issues of type 2 diabetes in children: a review. Pediatr 
Phys Ther 2007;19(3):211 -6.
25.Hannon TS, Rao G, Arslanian SA. Childhood obesit y and t ype 2 diabete s mellitus. Pedi atrics 
2005;116(2):473 -80.
26.International Diabetes Federat ion. Di abetes Atlas [book online]. Gan D, editor. 3rd ed. 
Brussels, Belgium: IDF; Copy right 2006. Updated 2008. http://www.eatlas.idf.org/. 
27.Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. 
Management of newly  diagnosed ty pe 2 Di abetes Mellitus (T2DM) in children and 
adolescents. Pedi atrics 2013;131(2):364-82.
28.International Diabetes Federat ion. Gl obal IDF/ISPAD Guideline for Diabetes in Childho od 
and Ado lescence [book online]. Copyright 2011. Accessed 23 June 2014. 
http://www.idf.org/sites/default/files/Diabetes- in-Childhood -and-Adolescence -Guidelines.pd
f. 
29.Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical tria l to maintain 
glycemic control in youth with t ype 2 diabetes. N Engl J Med 2012;366(24):2247 -56.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 79of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
30.Cram er JA. A systematic review of adherence wit h medicat ions for diabetes. Di abetes Care 
2004;27(5):1218 -24.
31.Kelsey  MM, Geffner ME, Guandalini C, Pyle L, Tamborl ane WV, Zeitler PS, et al. 
Presentation and effectiveness of early treatment of t ype 2 diabetes in youth: lessons from the 
TODAY study . Pedi atr Di abetes 2016;17(3):212-21.
32.Schwartz GJ, Work DF. Measurement and estimat ion of GFR in children an d adolescents. Clin 
J Am Soc Nephro l 2009;4(11):1832 -43.
33.Smart CE, Annan F, Bruno LP, Higgins LA, Acerini CL, Internat ional Societ y for P, et al . 
ISPAD Clinical Pract ice Consensus Guidelines 2014. Nutrit ional management in children and 
adolescents wi thdiabetes. Pedi atr Di abetes 2014;15 Suppl 20:135-53.
34.Marshall WA, Tanner JM. Variat ions in the pattern of pubertal changes in bo ys. Arch Dis 
Child 1970;45(239):13 -23.
35.Marshall WA, Tanner JM. Variat ions in pattern of pubertal changes in girls. Arch Dis Child 
1969;44(235):291 -303.
36.American Diabetes Associat ion. Foundations of Care and Comprehensive Medical Evaluat ion, 
Secti on 3. Diabetes Care 2016;39 Suppl 1:S23 -35.
37.Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, et al. ISPAD Clinic al Practi ce 
Consensus Guidelines 2014. Ty pe 2 di abetes in the child and adolescent. Pediatr Diabetes 
2014;15 Suppl 20:26 -46.
38.Hegazy  SK. Evaluat ion of the ant i-osteoporoti c effects of met formin and sitaglipt in in 
postm enopausal diabet ic women. J Bone Mi ner Metab 2015;33(2):207-12.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 80 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Appendix A Schedule of Study Procedures
AssessmentScreeningPre-Randomization 
Stabilization
Period (if needed)Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)End-of-
Treatment 
VisitFollow
-Up 
Visit
Screening 
Visit (b)At Least 
Every 
3 Months 
(b)Week 
-1Baseline 
Visit
(Day 1)4
(b) 1218 
(c) 2632 
(b) 3945
(b) 52 (a)54 
(a,b)
Visit windows (days)(Up to 14 
Days) ##2#7#7 #7 #7#7#7 #7 #2
Informed consent and 
assentX
Inclusion/exclusion X X (d) X (d)
Demographics;
medical history 
(including medication 
history and concurrent 
conditions)X
8-hour fast (e) X X X X X
Diabetes education 
(f)XX XX X X
Randomization X
Complete physical 
examinationX X X X
Brief physical 
examination (g)X X
Vital signs X X X X X X X X
Temperature X X X
Body weight and height X
X X X
12-lead ECG X X X X
Issue subject diary 
and glucometer X (h) X
Review diaries and 
glucometer readingsXX X X X X X
Review concomitant 
medications and 
PTE/AEsX (i) X X XX X X X X XX X ( i )
Hematology, serum 
chemistry XX X X X X
Lipid panel X X X X X
Amylase/lipase (k) X
Urinalysis X X X (l) X
C-peptide (n) X XCCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUp 
Visitsitof
52 (a)52 (amser
plicplic##li77ab
pic
eAeA pAppplpplppl
eApp
thetheee eeee
dS uSubjeject totoo tho thth
dSujeo
nd Snd SSdddSSS
ndS
OnlyyXXn
lynannn
lyn
ly
OnlyXXOnlylylyly
Use Ose OXO
UsUUUU
rcU
rcrcrcrc
mem
-Cn-Cn-Cn-Cn-C
No
FingsingsFFFo:F
omitant mitant
ns and s and 
EsEsda
matologymatol
chemistryemistfT
Lpeperty CCICCI
Alogliptin
Study No. SYR-322_309 Page 81 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
AssessmentScreeningPre-Randomization 
Stabilization
Period (if needed)Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)End-of-
Treatment 
VisitFollow
-Up 
Visit
Screening 
Visit (b)At Least 
Every 
3 Months 
(b)Week 
-1Baseline 
Visit
(Day 1)4
(b) 1218 
(c) 2632 
(b) 3945
(b) 52 (a)54 
(a,b)
Visit windows (days)(Up to 14 
Days) ##2#7#7 #7 #7#7#7 #7 #2
eGFR (o) X X X X
HbA1c X X X (p) X X X X X X
Tanner Stage scoring X X X
Serum pregnancy test 
(q)X X X X X
Urine (dipstick) 
pregnancy test (q)XX X
In-clinic dosingX X X X 
(s)X (t)
Access IVRS/IWRS X X X X X X
Dispense blinded 
study drug (u)X X X X
Document drug 
accountabilityX X X X
CD26 surface antigen X X X
Biomarker labs (v) X X X
GAD 65 and/or IA-2 
(w)XX
(a) Subjects who complete the 52-Week double-blind treatment period will complete an End-of-Treatment Visit and Follow-Up 
Visit, 2 weeks after the last dose of study drug. Subjects w ho terminate study drug prematurely w ill complete an En d-of-Treatment  
Visit and a Follow-Up Visit 2 weeks later and will continue to be followed for the 52-Week duration of the study and complete a 
Projected Week 52 Visit. The same procedures should be conducted at the Projected Week 52 Visit as the End-of-Treatment Visit
for subjects who prematurely discontinue the study. For sites not  able to conduct onsite visits due  to unavoidable circumstance s (eg, 
a widespread disease outbreak such as the COVID-19 pandemic or  natural disaster), acceptable alternatives to assess subject saf ety 
and overall clinical status may include, but are not limited to, visits as per protocol schedule conducted by delegated site st aff 
speaking directly with the subject by telephone or other medium (eg, a computer-based video communication), or sites may send site staff to subjects to conduct study assessments, contingent upon local regulations. 
The End-of-Treatment Visit should be performed in person. Alternative methods of data collection may be considered for this vis it 
when it is not possible for the subject to come to the study site. Under such circumstances, a preferred alternative for the vis it would 
be for site staff to go to the subjectâ€™s residence and conduct the protocol-specified procedures in that location. Assessments collected at subjectsâ€™ residence should comply with applicable local regulations. If neither option is available with sponsor o r 
designee approval, sites may conduct end-of-treatment procedures remotely as is feasible.
During contact with the subject by an alternative method, the study site physician or other qualified site staff should also, at  
minimum, conduct the following assessments within the visit: AE assessments, documentation of concomitant medication, drug 
accountability, and assessment of clinical symptoms. Other study assessments may be collected remotely as is feasible and may 
involve audio or video recording. Assessments that cannot be completed during the protocol-specified window will be considered missing data, and such departures will be recorded in the study records. Alternatively, sites may seek approval to extend the v isit 
window up to 3 times the protocol-specified window in order to conduct an onsite visit. The interval between successive visits when clinical laboratory tests and vital sign measurements are performed may not be longer than 8 weeks.
(b) The Screening Visit will be scheduled within 2 weeks pri or to Day 1 or prior to the start of the Pre-Randomization Stabiliz ation 
Period. During the Pre-Randomization Stabilization period, subjects will visit the study center at regular intervals according to the CCICCI
Property of Takeff--ffffkeda: For Non-Comeek doubek dou
of studystudy dr
weekseeks lat
he same phe same
urely discoely dis
outbreak soutbrea
status matatus m
y with they with 
ubjects to bjects t
TreatmTreat
is is not ponot p
or site stafr site s
ollected aected
designeedesig
DurinDuri
mmercial Use Only and Subjebjebjejeeje
dS uSuSubjSubjjbjjj
dSuj
nd Snd SXXSdddSSS
ndS
Onlyynnannn
lyn
se On yOn yOnlylyly
sy
UsUseXssseUsUUUUUU
XXiarc
meto the Applicable Terms of Usef
a))54 54 
(a,b(af
erof
##ble77Teeee
icicXabic
pppplicpplicicicic
ppic
AApAppppppppppApp
the Ahee Ae AAAAeA
ct tott ooto tto
mmebject
Alogliptin
Study No. SYR-322_309 Page 82 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
AssessmentScreeningPre-Randomization 
Stabilization
Period (if needed)Double-Blind Treatment Period
Weeks 1- 52 After Randomization (a)End-of-
Treatment 
VisitFollow
-Up 
Visit
Screening 
Visit (b)At Least 
Every 
3 Months 
(b)Week 
-1Baseline 
Visit
(Day 1)4
(b) 1218 
(c) 2632 
(b) 3945
(b) 52 (a)54 
(a,b)
Visit windows (days)(Up to 14 
Days) ##2#7#7 #7 #7#7#7 #7 #2
investigatorâ€™s discretion but at least every 3 months and at Week -1 prior to randomization. The Week 4, 32, 45, and 54 visits will 
be conducted only via telephone call to the subject. A follow-up visit will be conducted via telephone with the subject 2 weeks  after 
the End-of-Treatment Visit.
(c) The Sponsor or its designee will decide whether the Week 18 Visit will be conducted as an in-clinic visit, or optionally, a s a 
home health visit.
(d) The randomization criteria listed in Section 7.3will be assessed at the visits before Week -1 and all inclusion and exclusion 
criteria will be assessed at Week -1 prior to randomization.
(e) Subjects who have had the diagnosis of T2DM for less than 1 year and/or who are taking insulin at the time of randomization  
will be required to fast for at least 8 hours prior to the Screening or Week -1 visit for the assessment of fasting c- peptide. Subjects 
who are participating in postprandial glucose testing (refer to section 9.1.9.1)  will be required to fast for at least 8 hours prior to the 
visits indicated in the Schedule of Procedures.
(f) Subjects will be instructed on proper nutrition and exercise, how to recognize signs and symptoms of hypoglycemia, and the use 
of the glucometer.
(g) The brief physical exam will consist of the following body systems: (1) respiratory system; (2) cardiovascular system; 
(3) nervous system (4) dermatologic system; and (5) gastrointestinal system.
(h) During the Pre-Randomization Stabilization Period, the site will supply a glucometer to subjects who do not have one or cann ot 
obtain access to one. Subjects who do not enter the Pre-Randomization Stabilization Period should receive their glucometer (if 
needed) and diary at the Day 1 Visit.
(i) At the Screening visit, review only concomitant medications. At the Follow-up Visit, review only AEs.(j) Collected only from those subjects who arrive at the clinic in a fasted state.
(k) Serum amylase and serum lipase to be performed at Day 1 (Baseline Visit) for all subjects, and at an Unscheduled Visit for any 
subject who experiences persistent nausea and/or vomiting for â‰¥3 days with or without abdominal pain.
(l) The Week 26 urinalysis will only include quantitative assessments.(m)
(n) Required prior to randomization only for subjects who have had the diagnosis of T2DM for less than 1 year and/or who are 
taking insulin. 
(o) Calculated by the central laboratory.(p) HbA1c concentration should be â‰¥6.5% to <11.0% or â‰¥7.0% to <11.0% if the subject is on insulin. If this criterion is not met, the 
assessment may be repeated every 3 months.
(q) To be completed on all female subjects. If a urine pregnancy test yields a positive result, a serum pregnancy test must als ob e  
collected at the same visit and submitted to the central laboratory for confirmation of results. 
(s) Subjects may be dosed in the clinic if dose was not self-administered at home.
(t) (u) Subjects who meet the criteria for rescue will continue double-blind study medication, and continue to participate in the 
duration of the study. 
(v) The following labs will be collected at Baseline and at Weeks 26 and Week 52/End-of-Treatment: Bone specific alkaline 
phosphatase and C-terminal telopeptide.
(w) Collected once prior to randomization for subjects who have had the diagnosis of T2DM for less than 1 year and/or who are 
taking insulin at time of randomization.CCI
CCICCI
Property of T) Suubjectsbjeuu
(t) (t) 
(u) S(u) S
dudty oCCICCImmercial Use Only and Subject to the Applicab2, 45, and 45, and
h the subjehe sub
clinic visitnic vis
-1 and al1 and 
taking insking in
r the assethe ass
be requirbe requ
gnize signnize si
ms: (1) res(1) r
nal systemal syste
will suppwill supp
domizatiomiza
edicationsdicatio
at the clinithe cli
rmed at Dmed at
nd/or vom/or vom
ude quante quanable Terms of Usef
a))54 54 
(a,b(af
erof
##ble77Teeee
ab
omm
da: For Non-Comn only forn only fo
laboratorylaborato
should be ould b
eated eveated ev
d on all feon all 
ame visit me vis
f Takeda
Alogliptin
Study No. SYR -322_309 Page 83of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions.
The Investigator agrees to assume the fo llowing responsibilit ies:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authoriti es.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56 ICH, and local regulatory requirements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the study to the 
IRB/IEC and issue a final report within 3 mo nths of study  com pletion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50 ICH and local 
regul ations, are m et.
8.Obtain v alid inform ed consent from  each subject who participates in the study , and docum ent 
the date of consent in the subjectâ€™s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a subject authorizat ion section that 
describes the uses and disclosures of a subjectâ€™s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a subject authorizat ion, then the Invest igato r must obtain a separate subject authorizatio n 
form from each subject or the subjectâ€™s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resu lts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The Invest igator should 
contact and rec eive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 84of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 85of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix CElements of the Subject Informed Consent 
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subjectâ€™s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subjectâ€™s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of an y reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intende d clinical  benefi t to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statem ent describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written ICF, th e subject or the subjectâ€™s 
legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any medical treatments are available if i njury  occurs and, if so, 
what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study .
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(Invest igator), subjectâ€™s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statement that participation is v oluntary , that refusal to participate will invo lve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and that the subject may discont inue 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 86of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
participat ion at any  time wi thout penal ty or loss of benefits to which the subject is otherwi se 
entitled.
20.The consequences of a subjectâ€™s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subjectâ€™s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subjectâ€™s 
willingness to continue participat ion in the study .
22.A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws r equire the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subjectâ€™s participat ion in the study  
may be terminated.
24.A wri tten subject authori zation (either contained wit hin the ICF or provided as a separate 
docum ent) describing to the subject the contemplated and permissible uses and disclosures of 
the subjectâ€™s personal informat ion (including personal healt h informat ion) for purposes of 
conducting the study . The subject authorizat ion must contain the fo llowing statements 
regarding the uses and disclo sures of the subjectâ€™s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, i ncluding, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this count ry; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Take daâ€™s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subjectâ€™s ident ity will remain confident ia
l in the event that study  resul ts are 
published.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 87of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are se xually  active m ust use adequate contraception (as defined in the informed consent) 
from Screening throughout the duration of the study . Regular pregnancy  tests will  be 
perform ed throughout the study for all female subjects of childbearing potential. If a s ubject is 
found to be pregnant during study , study  medicat ion will be discont inued and the Invest igator 
will o ffer the subject the cho ice to receive unblinded treatment informat ion.
26.Male subjects must use adequate contraception (as defined in the informed consent) from 
Screening throughout the duration of the study. If the partner or wife of the subject is found to 
be pregnant during the study , the Invest igator will offer the subject the cho ice to receive 
unblinded treatment informat ion.
27.A statem ent that cl inical  trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 88of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix DInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of Invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, Invest igatorâ€™s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, US, and Japan), including the fo llowing:
ï‚·Takeda, its affiliates, and licensing partners.
ï‚·Business partners assist ing Takeda, its affiliates, and licensing partners.
ï‚·Regulatory  agencies and other health authorit ies.
ï‚·IRBs and IECs.
Invest igatorâ€™s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
ï‚·Assessment of the suitabilit y of Invest igator for the study  and/or other clinical studies.
ï‚·Management, mo nitoring, inspect ion, and audit of the study .
ï‚·Analysis, review, and verificat ion of the study  results.
ï‚·Safety reporti ng and pharmacovigilance relat ing to the study .
ï‚·Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regulatory  agencies rel ating to the study .
ï‚·Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound pre sent in the study  medicat ion.
ï‚·Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
ï‚·Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
ï‚·Archiving and audit of study  records.
ï‚·Posting Invest igator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igatorâ€™s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in Invest igatorâ€™s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 89of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix ECollection, Shipment, and Storage of Pharmacokinetic Samples
Instructions for Processing of Plasma Samples for Pharmacokinetic Analysis of Alogliptin 
(SYR -322)
1. Collect 3 mL of venous blood into a chilled Becton- Dickinson v acutainer. For all aloglipt in 
samples, blood samples should be co llected into vacutainers containing potassium 
ethylenediamine tetraacetic acid (K 2EDTA). 
2.Gent ly invert the vacutainer several t imes to mix the addit ive wit h the collected blood prior to 
centrifugation and place immediately on ice. 
3.Centrifuge the vacutainers for 10 minutes at approximately 1100 to 1300 (relat ive centrifugal 
force) at approximately 4Â°C in a refrigerated centrifuge. Note: if using a collect ion device other 
than Becton -Dicki nson, refer to manufacturerâ€™s instruction for proper centrifugation force and 
time. 
4.Immediately fo llowing centrifugat ion, gent ly remove plasma fro m the packed cells. To ensure 
a more hom ogeneous sample, all plasma should first be transferred into 1 aliquo t. From there, 
split the plasma evenly between the 2 aliquots. A minimum o f 0.6 mL needs to be obtained for 
each sample. Labeling may include protocol number (SYR322_309), matrix (ie, plasma), 
analyte (aloglipt in), subject number, nominal day and time, and either â€œSET 1â€ (for ori ginal  
sample) or â€œSET 2â€ (for duplicate sample). 
5.Cap the labeled storage tubes and freeze the plasma samples immediately at approximately 
-20Â°C or lower. No more than 45 minutes will elapse between blood collect ion and freezing the
plasma sample. 
6.Keep samples frozen at approximately -20Â°C or lower until shipment to PPD central laboratory. 
SET 1 samples will be shipped first on dry  ice, followed by  shipment of duplicate SET 2 
samples after SET 1 samples have been received by  the ana lytical laboratory .
Instructions for Shipping of Samples for Pharmacokinetic Analyses 
Site may adhere to the siteâ€™s Standard Operating Procedures on shipping samples if the Standard 
Operating Procedure differs from the sample instructions provided.
Biological samples should be shipped on dry ice to prevent thawing during transit. Ship samples 
only on Monday, Tuesday , or Wednesday, and at least 2 day s prior to a nati onal holiday, to 
minimize the possibilit y of samples in transit over a weekend or holiday . If duplicate sam ples are 
to be shipped, send SET 1 samples and await confirmat ion of arrival before shipping the duplicate 
SET 2 samples.
1.Before shipping, make sure the sample tubes are tight ly sealed. Separate each subjectâ€™s 
samples as fo llows:
2.Separate th e duplicate SET 2 samples from the SET 1 samples.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 90of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
3.Place SET 1 sam ples f or each subject into zipper lock bag con taining addit ional absorbent 
materi al.
4.Using a permanent marker, write the randomizat ion number, sample matrix (ie, plasma), 
analyte, number of s amples, and â€œSET 1â€ on each zipper lock bag.
5.Place the bags of individual subjectâ€™s samples into a larger plast ic bag so that samples are 
doubl e bagged. Duplicate SET 2 samples should be returned to the freezer for storage. Repeat 
steps 3 -6 above when preparing duplicate samples for shipment, except zipper lock bags 
shoul d be marked â€œSET 2.â€
6.An inventory  of individual  samples shoul d acco mpany each shipment and should include the 
sponsorâ€™s name (Takeda), study  drug (al oglipt in), protocol number (SYR -322_309) , 
Invest igatorâ€™s name, sample t ype (ie, plasma, subjectâ€™s randomization number, no minal 
collect ion day  and time, and intended sample storage condit ions. When duplicate SET 2 
samples are being shipped, make a copy  of the original SET 1 sample inventory  and mark as 
â€œSET 2.â€ Pl ace the inventory  paperwork into a large zipper lock bag. SET 1 samples will be 
shipped first on dry ice, fo llowed by shipment of duplicate SET 2 samples after SET 1 samples 
have been received by  the analy tical laboratory .
7.For sample pac king, utilize dry  ice generously  (eg, 20 -25 pounds per day of transit) to 
safeguard against longer than expected shipping times and delays. Use newspaper or other 
materi al to insulate the doubl e-bagged samples from direct contact with the dry  ice. Pl ace th e 
sample bundles into a Sty rofoam container (or other suitable container) and fill the excess 
space with dry  ice slabs or i ce pellets (preferably the latter). Make a note of the estimated 
weight of  the dry  ice used per shipping container.
8.Place the invento ry paperwork (in a large zipper lock bag) on top of the dry  ice in the 
Styrofoam container. Pl ace the lid on the Sty rofoam container and seal com pletely  with 
strapping tape. Place the St yrofoam container in a cardboard shipping carton and seal securely 
with strapping tape.
9. Mark the outside of shipping carton(s) with a tally number (eg, 1 of 5, 2 of 5).
10.Affix an address label to each shipping carton by  send the samples to PPD central laboratory .
11.Affix a carbon dio xide label on each carton, specifically:
Carb on Di oxide Solid UN -1845
Class 9 PKG GR III
Quant ity _____________________
(fill in weight to nearest lb/kg and specify unit of measure used)
12.Affix 2 dry  ice symbo l labels on opposite sides o f the carton. Mark KEEP FROZEN on each 
carton. Specify  a return a ddress and contact person on the carton.
13.Obtain the airway bill number and a receipt of shipment fro m the carrier.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 91of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
14.After shipping o f the samples, contact PPD central laboratory for all samples to notify them o f 
next day  delivery. When calling, provide the following informat ion:
Nam e of couri er or transport com pany
Time and date the shipment left the clinical site
Airway  bill number
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 92of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix FCollection, Shipment, and Storage of Pharmacogenomic Samples
Collect 1 mL who le blood for DNA i solation before dosing on Day  1 into pl astic potassium 
ethylenediamine tetraacetic acid (K 2EDTA) spray -coated tubes fro m each subject which signs the 
optional pharm acogenomic sample collection ICF.
Collect 2.5 mL who le blood for RNA iso lation at predose on Day  1 and Week 12 into a PaxGene 
TM tube.
A saliva sample will also be obtained fro m the subject at Day  1.
For detailed instructions on sample co llection and storage follow the laboratory  manual  provided 
by the central laboratory .
Sample Shipmen t
Ship samples only  on Monday, Tuesday , or Wednesday , and at l east 2 day s prior to a nati onal 
holiday, to minimize the possibilit y of samples in transit over a weekend or holiday . The 
laboratory  must confirm arrival o f the shipped sampl es.
For instructions on shipping and packing fo llow the l aboratory  manual  and shipping instructi ons 
provi ded by the central laboratory .
Before shipping, ensure the sample tubes are tightly sealed.
Sample Storage
The DNA and RNA samples will be stored in a secure storage space with adequate m easures to 
protect confident iality. The samples will be retained while research on aloglipt in cont inues for up
to but not longer than 15 years or as required by applicable law.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 93of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix G Determination of Eli gibility in Subjects With Elevated ALT Levels 
*Liver biopsies are not required, however, may be recommended by the investigator to confirm NAFLD and thereby, 
render the subject eligible for the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 94of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix HRecommend ations for Home Glucose Monitoring
Subjects should be advised to check their blood glucose levels on a daily basis, at the fo llowing 
time points, at a minimum:
ï‚·Two times per day .
â€“In the m orning upon awakening (fast ing).
â€“One addit ional time (for example, be fore dinner, or 2 hours after dinner).
ï‚·Addit ional test ing of blood glucose levels is reco mmended during periods of illness, or when 
signs or symptom s of hypoglycemia are thought to be experienced. 
ï‚·Addit ional testing of blood glucose levels is also recommended during the study, such as whe n 
rescue m edicati ons are requi red and/or when rescue medicat ions are being down -titrated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 95of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Appendix IProtocol History
Date Amendment Number Amendment Type Region
17August 2020 Amendment 9IT v 1 Substantial Italy
13November 20 19 Amendment 8 Substantial Russia
28November 20 18 Amendment 7 Substantial Brazil
27June 2018 Amendment 6 Substantial Germany
09February  2018 Amendment 5 Substantial Germany
17January 2018 Amendment 4 Substantial Italy
10May 2017 Amendment 3 Nonsubstantial Global
09November 20 16 Amendment 2 Substantial Global
29April2016 Amendment 1 Substantial Global
28July2015 Initial Protocol Not applicable Global
Protocol Amendments 5through 8: 
Protocol  Amendments 5through 8 were l ocal amendments applicable to single countries other 
than Italy ; therefore, details of these amendments are not included in this localprotocol  
amendment for Italy .
Protocol Amendment 4 Italy Summary and R ationale 
The primary  purpose of thi s country -specific amendm ent for Italy  was to incorporate suggested 
changes made by the central ethics co mmittee (CEC) and the local regulatory  authori ty in Italy.
In a l etter dated 23 October 2017, the CEC stated the ne ed to cl arify the ri sk for treatm ent-naÃ¯ve 
subjects in the event of assignment to the placebo group. In a letter dated 30 October 2017 (â€œA 
Denial o f Authorisationâ€ issued by the Agenzia Italiana del Farmaco [AIFA] for the Clinical Trial 
Applicat ion for Stu dy SYR 322_309), AIFA provided feedback on exclusio n criterion 7 (â€œThe 
subject has had more than 1 episode of diabetic ketoacidosis at any time after diagnosis of T2DMâ€) 
and exclusio n criterion 8 (â€œThe subject has a history  of more than 1 epi sode of pancre atitisâ€). 
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
Protocol Amendment 4 Italy
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 2.0 STUDY SUMMARY
Section 6.1 Study Design
Figure 6.a Schematic of Study Design
Section 7.2 Exclusion Criteria
Section 7.3 Additional 
Randomization Criteria That Must Be Excluded treatment -naÃ¯ve subjects. The CEC raised objection to 
including naÃ¯ ve subjects (â€œThe 
Committee does not consider the 
clarificatio ns provided to be 
thorough and reiterates the need to 
clarify  the risk for naÃ¯ve patients in 
the event they are assigned to the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR -322_309 Page 96of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Protocol Amendment 4 Italy
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Met Following Screening and/or 
Completion of the Pre -Randomization 
Stabilization Period
Section 13.1.3 Efficacy Analysisplacebo groupâ€). In order to be 
compliant with CEC requests, 
treatment -naÃ¯ve subjects were 
excluded in this local amendment 
for Italian subjects.
Section 7.2 Exclusion Criteria
Section 8.3 Randomization Code 
Creatio n and StorageExcluded subjects with a history of 
diabetic ketoacidosis (DKA).Because this is a clinical trial 
involving a pediatric population 
and DKA is a serious clinical 
disease, the benefit -risk ratio 
cannot be considered favorable in 
subjects with a history of DKA. 
This change ensures that the 
inclusion of subjects at risk for 
DKA will be minimized.
Section 7.2 Exclusion Criteria Excluded subjects with a history of 
pancreatitis.Because this is a clinical trial 
involving a pediatric population 
and pancreatitis is a serious clinical 
disease for which, in the vast 
majority of the cases, it is 
impossible to identify a cause in 
the target age group, the 
benefit -risk ratio cannot be 
considered favorable in subjects 
with a history of pancreatitis. This 
change ensures that the inclusion of 
subjects at risk for pancreatitis will 
be minimized.
Protocol Amendme nt 3 Summary and Rationale
This sect ion describes the changes in reference to the protocol incorporating Amendment 3. The 
primary  purpose of this amendment was to provide updated contact informat ion. A number of 
editorial changes were m ade throughout the p rotocol to provide clarit y. The fo llowing is a 
summary of the changes made in the amendment.
Protocol Amendment 3
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 1.1 Contacts Updated contact information. To reflect personnel changes.
Section 1.2 Approval Updated list of protocol approvers. To reflect personnel changes.
8.1.1.2 Companion Medication Rem oved the provision of pharmacy 
cards for companion medications by The use of pharmacy cards was 
removed to allow more flexibility 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 97 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Protocol Amendment 3
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
deleting Section 8.1.1.5 Pharmacy Card Supplied Drugs.on how companion medications 
can be obtained. 
Section 8.1.1.3 Rescue Medication
Section 8.1.1.6 Rescue MedicationsCombined text for rescue 
medications.To consolidate text in 2 different 
sections for rescue medications. 
Protocol Amendment 2 Summary and Rationale
This section describes the changes in reference to the protocol incorporating Amendment 2. The 
primary purpose of this amendment is to enhance clarity, provide additional guidance, and remove 
unnecessary procedures. A number of editorial and administrative changes were made throughout 
the protocol to provide clarity. The following is a summary of the changes made in the 
amendment.
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 1.1 Contacts Updated contact information. To reflect personnel changes.
Section 1.2 Approval Updated list of protocol approvers. To reflect personnel changes.
Section 5.2.2 Secondary Endpoints
Section 2.0 Study SummaryAdded respiratory tract infections 
and hypersensitivity reactions, in addition to total and urinary tract infections, to the â€œincidence of infectionsâ€ in the safety endpoints.To align with adverse events of 
special interest.
Section 5.2.2 Secondary Endpoints
Section 5.1.2 Secondary ObjectivesSection 9.1 Study Procedures
Section 13.1.1 Analysis Sets
Appendix A Schedule of Study 
ProceduresRemoved dual-energy x-ray
absorptiometry scans.These scans are not needed as DPP-4 
inhibitors have not shown an impact 
on bone density in clinical studies.
Section 5.2.3 Exploratory Endpoints
Section 2.0 Study SummaryTable 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
ProceduresTo align with planned analyses.
Section 6.2 Pre-Randomization 
Stabilization Period (if needed)Modified the length of time for the 
maintenance of stable anti-hyperglycemic therapy from 1 month to 2 months.To allow more time for stabilization.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefffofooo
cations ations m
in 2 diffin 2 d
ue medice medeT
ica
rating Arating
ditditioionalna
e changchan
 the chathe ch
nt 2nt 2S
al VersioVersnd
scriptioncriptya
On yntact inftact eO
d list of pd list ofUs
ded respied resp
and hynd hy perpyyyy
additioaddit
infein
ial
m
dpopointsints
ObjectivObject
ocedurescedur
nalysis Selysis 
Schedule cheduCo
n 5.2.3 Exn 5.2.3 E
tion 2.0 Son 2.
Table 9.aable 9
AppeApp
PrPke
peppp
Alogliptin
Study No. SYR -322_309 Page 98of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 6.2 Pre -Randomization 
Stabilization Period (if needed)Added recommendations regarding 
managing insulin therapy.To provide more guidance to the 
investigator.
Section 7.1 Inclusion Criteria and 7.3 
Additional Randomization Criteria 
That Must Be Met Following 
Screening and/or Completion of the 
Pre-Randomization Stabilization 
Period
Section 2.0 Study Summary
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
ProceduresClarified that inclusion criteria 
regarding C-peptide, autoantibodies, 
age, and BMI apply at randomization 
and that C-peptide, autoantibodies, 
and BMI criteria apply to subjects 
who have had the diagnosis of T2DM 
for less than 1 year and/or who are 
taking insulin.Applied criteria to the pediatric 
diabetic pop ulatio n to those most at 
risk for misdiagnosis of type 1 
diabetes and to align with clinical 
practice guidelines. Also, clarified 
that these criteria are to be met prior 
to randomization.
Section 7.2 Exclusion Criteria
Section 7.9 Renal Safety Withdrawal 
Criteria
Table 9.a Clinical Laboratory Tests
Section 16.0 ReferencesChanged eGFR calculations to be 
based on the Schwartz formula rather 
than Cockcroft -Gault.The Schwartz formula is a more 
appropriate formula than the 
Cockcroft -Gault formula for the 
estimation of GFR in the pediatric 
populatio n.
Section 7.2 Exclusion Criteria Modified wording of exclusion 
criteria regarding sexual activity to 
align with Section 9.1.9.Clarified wording to align with 
Section 9.1.9.
Section 7.3 Additional 
Randomization Cr iteria That Must 
Be Met Following Screening and/or 
Completion of the 
Pre-Randomization Stabilization 
Period
Section 2.0 Study Summary
Figure 6.a Schematic of Study 
Design
Section 6.2 Pre -Randomization 
Stabilization Period (if needed)
Appendix A Schedule of Study  
ProceduresAdded a randomization criterion for 
subjects on insulin to require and 
HbA1c level of â‰¥7.0%.This criterion threshold was raised 
for subjects on insulin to allow for 
additional therapy before they reach 
their treatment goal and to minimize 
the risk of hypoglycemia.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Alogliptin
Study No. SYR-322_309 Page 99 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 7.3 Additional Randomization Criteria That Must Be Met Following Screening and/or Completion of the 
Pre-Randomization Stabilization 
Period
Section 2.0 Study Summary
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
ProceduresUpdated laboratory testing 
terminology from ICA 512 antibody to IA-2 antibody.To match the terminology used by 
the laboratory.
Section 7.4 Excluded Medications Added clarification regarding the use 
of oral or parenteral steroids during the treatment period.Chronic steroid use impacts glucose 
levels and therefore, may affect measurements of HbA1c, which is primary endpoint . For this reason, the 
chronic use of steroids should be avoided if possible.
Section 7.9 Renal Safety Withdrawal CriteriaAdded wording to the renal safety 
withdrawal criteria to clarify that the confirmation by a repeat laboratory test is to be conducted within a maximum of 7 days.Clarified that repeat testing should 
occur within a specified period of time.
Section 9.1.3 Physical Examination ProcedureAdded details regarding assessment 
of pubertal development.Added menarche and clarification of 
Tanner stage categories.
Section 9.1.4 Weight, Height and BMIAdded clarification regarding BMI 
measurements.Clarified the process for BMI 
measurements.
Section 9.1.7 Documentation of Concurrent Medical ConditionsAdded a recommendation for annual 
ophthalmologic examinations.To monitor the subjects for 
retinopathy, one of the known complications of T2DM.
Section 9.1.8 Procedures for Clinical Laboratory SamplesAdjusted the volume of blood 
collected for clinical laboratory samples.Blood volume was adjusted based on 
updated laboratory tests.
Table 9.a Clinical Laboratory Tests
Section 9.1.8.1 2-Hour Postprandial 
Glucose Test
Table 9.b 
Appendix A Schedule of Study 
ProceduresRemoved insulin and proinsulin 
measurements and clarified that 
C-peptide will only be measured 
once prior to randomization.These measurements were removed 
as they were expected to produce 
inconclusive results in pediatric 
patients treated with diet and exercise, insulin, and/or metformin.
Table 9.a Clinical Laboratory Tests
Appendix A Schedule of Study 
ProceduresClarified that GAD and IA-2 
antibody testing may be performed by the central laboratory.These tests may be performed by the 
central laboratory.CCIClinical Clinica
n 9.1.8.1n 9.1.8
cose Tesose T
Table 9.bable 9
AppeAppda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefffofooo
used by ed bym
cse 
ing ng ChroCh
leccctjec
o the renao the re
teria to cria to
n bybya reayy
be condube con
mum of 7um of ly
dded detaded de
of puberof pubia
AddAd
mmm
of 
itionsionsCo
dures fordures 
pleslesr
PrPed
pep
Alogliptin
Study No. SYR-322_309 Page 100 of 101Protocol Incorporating Amendment No. 9 IT v1 17 August 2020
Protocol Amendment 2
Summary of Changes Since the Last Global Version of the Approved Protocol
Sections Affected by Change Description of Each Change and Rationale
Location Description Rationale
Section 9.1.8.1 2-Hour Postprandial Glucose TestAdded clarification regarding 
postprandial glucose testing.Approval of the meal is not required. 
Also, oral glucose tolerance testing was added as an option for measuring postprandial glucose at sites who to 
do not have the ability to perform 
standardized meal tests.
Section 12.1 CRFs (Electronic) Made a correction to the eCRF 
process regarding data changes after database lock.These statements were removed to 
reflect the data handling process.
Section 16.0 References Added recent literature references. To provide additional information.
Appendix A Schedule of Study ProceduresAdded hematology and serum 
chemistry testing at the Week -1 Visit.To specify time point.
Appendix A Schedule of Study 
Procedures
Appendix A Schedule of Study Procedures
Table 9.a Clinical Laboratory TestsAdded eGFR measurements at 
Baseline and at Weeks 26 and 52.To monitor for renal safety.
Appendix A Schedule o fStudy
ProceduresAdded clarification regarding 
inclusion/exclusion criteria assessments and in-clinic dosing to the schedule of assessment.Footnotes were added for 
clarification. 
Rationale for Amendment 1
The primary purpose of this amendment was to e nhance clarity and simplify the study design to 
more closely align with standard of care practices and reduce the overall burden on subjects and 
caretakers throughout the duration of the study. A number of editorial and administrative changes 
were made throughout the protocol to provide clarity. 
Changes in Amendment 1
1. Study entry criteria were modified, incl uding broadening glycosylated hemoglobin (HbA1c)
criteria and hepatic enzyme criteria, in order to better reflect the study population and allow 
subjects with non-alcoho lic fatty liver disease ( NAFLD) into the study.
2. The number of schedules was reduced in order to simplify the study design.CCI CCI
Property of Takeda: For Non-Commercial Use Only anR measuR me
and at Wand ateO
Added cladded c
inclusiinclus
asseas
thciad Subject to the Applicable Terms of Usefffofooo
requiredrequir
nce testinnce tes
n for mean for m
se at sitee at sit
ability toability t
meal tesmeal tem
tements ements 
the data he dapp
To provio prot
To spTott
jec
Su
Com
mendmmendm
purpospurpo
selylyalalyyigi
kers throkers thr
e me made ad
ChangChan
1.1dS uand 
Alogliptin
Study No. SYR -322_309 Page 101of 101
Protocol Incorporating Amendment No. 9 IT v1 17August 2020
3.A Pre -Rando mization Stabilizat ion Peri od was added for those subjects who are not y et 
stabilized on their current ant idiabet ic therapy or who have not yet met certain entry criteria.
4.The gui dance for hepati c safet y monitoring and withdrawal criteria was revised to ref lect the 
potenti al inclusi on of subjects wi th NAFLD. 
5.The assessment of retinopathy  by fundus photography was rem oved as this microvascular 
complicat ion is very  unlikely  to have m anifested at this early stage in the natural history  of 
T2DM in this populat ion to warrant evaluat ion. 
6.Hom e glucose m anagement and hyperglycemic rescue language were clarified to allow 
investigators to individualize glucose management based on the needs of the subject and 
according to local guidance. 
7.The schedule of assessments w as adj usted to decrease the number of clinic visits, allow for 
telephone visits, and minimize fasting requirements in order to reduce the burden on subjects.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
(/(&7521,& 6,*1$785(6
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm â€˜UTCâ€™) 
GFä£ƒä£¯ä£§ä£°ä£¦ä£¯ä£§ä£°ä£¶ä¢¢ä¢»ä¢¢ä£‹ä£–ä¢¢ä£¸ä¢³ä¢¢ä£¶ä£±ä¢¢ä£ƒä¢¢ä£ä£·ä£®ä£¶ä£«ä£¥ä£§ä£°ä£¶ä£§ä£´ä¢®ä¢¢ä£”ä££ä£°ä£¦ä£±ä£¯ä£«ä£¼ä£§ä£¦ä¢®ä¢¢ä£†ä£±ä£·ä£¤ä£®ä£§ä¢¯ä£„ä£®ä£«ä£°ä£¦ä¢®ä¢¢ä£’ ä£®ä££ä£¥ä£§ä£¤ä£±ä¢¯ä£…ä£±ä£°ä£¶ä£´ä£±ä£®ä£®ä£§ä£¦ä¢¢ä£•ä£¶ä£·ä£¦ä£»ä¢¢ä£¶ä£±ä¢¢ä£‡ä£¸ä££ä£®ä£·ä££ä£¶ä£§ä¢¢ä£¶ä£ªä£§
ä£‡ä£¨ä£¨ä£«ä£¥ä££ä£¥ä£»ä¢¢ä££ä£°ä£¦ä¢¢ä£•ä££ä£¨ä£§ä£¶ä£»ä¢¢ä£±ä£¨ä¢¢ä£ƒä£®ä£±ä£©ä£®ä£«ä£²ä£¶ä£«ä£°ä¢¢ä£…ä£±ä£¯ä£²ä££ä£´ä£§ä£¦ä¢¢ä£™ä£«ä£¶ä£ªä¢¢ä£’ä£®ä££ä£¥ä£§ä£¤ä£±ä¢¢ä£«ä£°ä¢¢ä£’ä£§ä£¦ä£« ä££ä£¶ä£´ä£«ä£¥ä¢¢ä£•ä£·ä£¤ä£¬ä£§ä£¥ä£¶ä£µä¢¢ä£™ä£«ä£¶ä£ªä¢¢ä£–ä£»ä£²ä£§ä¢¢ä¢´ä¢¢ä£†ä£«ä££ä£¤ä£§ä£¶ä£§ä£µä¢¢ä£ä£§ä£®ä£®ä£«ä£¶ä£·ä£µ
%LRVWDWLVWLFV$SSURYDO -XQ87&
&OLQLFDO6FLHQFH$SSURYDO -XQ87&PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm â€˜UH:mmTer
ble87&87&
